

# Vaccines and Global Health: The Week in Review 12 November 2022 :: Issue 679 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <a href="https://centerforvaccineethicsandpolicy.net">https://centerforvaccineethicsandpolicy.net</a>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

### Contents [click to move among sections]

- :: Coronavirus [COVID-19] WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

### **Milestones, Perspectives**

::::::

### WHO releases first data on global vaccine market since COVID-19

9 November 2022 News release

- This the first report to capture the implications of COVID-19 for vaccine markets.
- Despite progress in recent decades, global market vaccine dynamics are not fully conducive to the development, supply and access for vital vaccines for public health.
- Vaccines prioritized by WHO are not being developed or fully invested in due to limited profit potential.
- Lower-income countries have struggled to access critical vaccines such as against COVID-19 in 2021 and cervical cancer vaccine that are in-demand by wealthier countries.
- Some regions depend almost entirely on others for vaccine supply.
- WHO calls on governments, manufacturers and partners to take ambitious action to guarantee equitable access to vaccines and improve responses to future pandemics.

WHO's <u>Global Vaccine Market Report 2022</u>, published today, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently struggling to access vaccines that are in-demand by wealthier countries...

"The right to health includes the right to vaccines," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "And yet this new report shows that free-market dynamics are depriving some of the world's poorest and most vulnerable people of that right. WHO is calling for much-needed changes to the global vaccine market to save lives, prevent disease ad prepare for future crises."...

::::::

### **Global Vaccine Market Report 2022**

A shared understanding for equitable access to vaccines

9 November 2022 | Publication :: 60 pages

PDF: <a href="https://cdn.who.int/media/docs/default-source/immunization/vaccine\_access\_market/global-vaccine-market-report-2022-template-final2.pdf?sfvrsn=5e8ddbed\_6&download=true">https://cdn.who.int/media/docs/default-source/immunization/vaccine\_access\_market/global-vaccine-market-report-2022-template-final2.pdf?sfvrsn=5e8ddbed\_6&download=true</a>

#### **Overview**

The report aims to capture lessons from the COVID-19 pandemic and to highlight the opportunity for more ambitious global action: expanding sustainable access to vaccines for all towards the Immunization Agenda 2030 and pandemic prevention, preparedness and response efforts. The report is organized in two sections: the first section provides WHO insights on global vaccine market dynamics, drawing from data provided by Member States, which are, in turn, analysed and displayed in the second section.

### **Executive Summary** [Editor's text bolding/formatting]

The past two decades have seen important progress in access to vaccines of public health importance, with new vaccines developed and distributed globally, saving millions of lives and averting disease. Nevertheless, an extensive assessment of global vaccine market dynamics still shows significant challenges.

The many new vaccines developed against key diseases, such as meningococcal meningitis A, hepatitis E and malaria, translate into millions of lives saved. However, diseases associated with markets of little commercial value remain neglected and face suboptimal investment, few products in the development pipeline, extended timelines and delays in availability.

There is a large and expanding manufacturing base, with more than 90 manufacturers supplying vaccines to World Health Organization (WHO) Member States in 2021. However, supply remains highly dependent on fewer than 10 manufacturers with broad portfolios, global reach and a diversity of deployable technology. Even more importantly, when looking at individual vaccines, often only two or three suppliers provide most of the supply. Trends are positive, with an increased contribution of manufacturers from additional countries, but more distributed manufacturing capabilities are needed. This concentration leads to market health issues and regional supply insecurity, particularly in the African and Eastern Mediterranean Regions, making access to vaccines heavily dependent on the policies and supply chains of other regions.

In addition, vaccine supply has historically been unable to rapidly respond to significant changes in demand, both owing to technological challenges and to a lack of market incentives. Vaccines are typically manufactured in product-specific facilities and product changeovers are cumbersome, limiting flexibility. At the same time, manufacturing know-how, intellectual property rights protection, non-linear production costs, uncertain demand and displacing competition limit manufacturer incentives to scale up.

Coordinated procurement and financing mechanisms, particularly for lower-income settings, have reduced gaps in access, enhancing earlier availability in lower-income countries and more favourable vaccine pricing. Yet, equitable and efficient distribution of vaccines continues to suffer, as indicated by vaccines such as for pneumococcus and human papillomavirus.

**On the demand side**, important efforts have been made to support country planning, forecasting and budgeting: predictable country demand is key to guiding investments. However, more investment and focused effort are needed to facilitate universal vaccination with all recommended products and to enhance the diversification of the vaccines procured, increasing the reach of the vaccination programme and counter the growing threat of vaccine hesitancy. It is important that the contribution of vaccines to the well-being and prosperity of citizens is fully recognized and that clear vaccine programme priorities and objectives are set, proper planning is executed and budgetary appropriations are made accordingly.

### The COVID-19 pandemic has given unprecedented visibility to vaccine market dynamics and has shown that some of these challenges can be overcome.

The vaccine community made new vaccines available in less than one year while using innovative technology platforms that enabled faster scalability. This achievement resulted from unprecedented public investment, early and parallel at-risk investment in clinical development and manufacturing capacity and the streamlining of regulatory processes. Those factors, combined with the size of the population targeted by COVID-19 vaccines, led to a three-fold increase in vaccine doses procured globally within 12 months.

This incredible achievement in the face of a public health emergency of international concern made stark the long-standing need to reconsider the value of vaccines as a fundamental and cost-effective public good rather than a commodity.

We must acknowledge both that vaccines are under-invested and that free-market dynamics do not optimize for social and health impact. Without strong public engagement, the strategic focus and investments of manufacturers will remain limited relative to the need for an ambitious immunization agenda and will continue to concentrate on more profitable pharmaceutical interventions and on high-income market vaccines.

COVID-19 has also shown that large public investment, streamlined processes, new technologies, pooled financing and procurement are not sufficient to achieve optimal public benefit. Efficient and equitable access to COVID-19 vaccines has been highly problematic as a result of dynamics repeatedly experienced in other vaccine markets.

The lack of transparency along the value chain of vaccine manufacturing and distribution and the lack of government oversight made it hard for governments to plan and use vaccines most efficiently within national boundaries as well as across countries. Despite the impressive number of approximately 15 billion doses delivered globally through various mechanisms as of October 2022, COVAX accounted for only 12% of this volume, indicating that serving all populations more equitably and ending future pandemics requires more than financing and procurement efforts.

We need to enhance government oversight of vaccine production and distribution and strike a much better balance between serving national interests and global public health objectives. The only means to achieve this is through high-level diplomacy between countries and pre-defined and binding rules for vaccine distribution at a time of scarcity. We also must work on a more favourable intellectual property landscape, proactive technology transfers and the building and retention of local technical and regulatory capacity. We should acknowledge that additional dedicated and permanent manufacturing capacity is costly and should be valued not only as means to satisfy current vaccine demand but also as an insurance against future public health needs.1

We have an opportunity to establish a new paradigm for vaccine development and access that builds on new practices and some of the lessons learned during the COVID-19 pandemic. This new paradigm could be incorporated as part of a new international accord on pandemic prevention, preparedness and response.

### In this new paradigm, we call for stakeholders to assume their shared but differentiated responsibilities; that is, for governments to commit to:

- 1. Establish early, evidence-informed strategic goals and leadership that serve the collective global health interest and to shoulder risks and invest aggressively in order to address the needs of today and prepare for future emergencies.
- 2. Strengthen market preparedness by investing in new vaccine technologies, regional research and development and manufacturing hubs, and by enabling regulatory harmonization.
- 3. Ensure transparency and oversight along the vaccine value chain towards enhanced health impact, as well as, define principles and operational mechanisms for collaboration across countries in times of scarcity, including for intellectual property and the circulation of inputs and goods.

### We call on industry to commit to:

- 1. Ensure that activities are aligned with WHO's guidance: research and development efforts focused on the WHO list of priority pathogens and target product profiles, more clinical trials performed in low-income countries, and targeted to inform global policy needs and expedited data submissions for regulatory approvals and prequalification.
- 2. Establish provisions for technology transfer and ensure transparency along the vaccine value chain.
- 3. Commit to specific measures allowing for equity-driven allocation of products.

### And we call on international organizations and partners to commit to:

- 1. Prioritize the achievement of global public health priorities as per the Immunization Agenda 2030 as an umbrella for individual organizational strategies, priorities and interests.
- 2. Support country-driven initiatives and projects consistently with organizations' missions and avoid the creation of duplicate efforts.
- 3. Continue to call for technology transfer and for the application of resolutions on market transparency for health products.

In the next pandemic, this paradigm would serve both equity and national interests by reducing disease everywhere through a faster, more coordinated and more equitable global response. Between pandemics, this paradigm would enable bolder, coordinated leadership to improve access to vaccines for all.

::::::

### **Featured Journal Content**

### **BMJ Global Health**

November 2022 - Volume 7 - 11 https://gh.bmj.com/content/7/11

Commentary

### A global social contract to ensure access to essential medicines and health technologies (11 November, 2022)

Katrina Perehudoff, Veronika J Wirtz, Anna Wong, Violet Rusu, Jillian Kohler *Summary box* 

- The COVID-19 pandemic illuminates the need to move away from the current social contract, which focuses on the nation-state's responsibility for protecting the health of its own population, including by providing essential medicines and health technologies.
- We argue for embracing a global social contract, which is a governance concept that lays the foundation for how states should act as members of the international community, as regulators of the private pharmaceutical industry and as guarantors of public goods benefiting people worldwide.
- A global social contract should be based on a set of four principles: collective state stewardship of the pharmaceutical and health technology; equity and the protection of health as a human right; an effective global polity; and governmental transparency and democratic accountability.
- This foundation can serve as a basis for a future pandemic treaty and as a model to address the much broader global crisis of inequitable access to medicines and health technologies for infectious and non-communicable diseases.

### **Conclusions**

The COVID-19 pandemic has starkly highlighted the failings of our current social contract and the lack of a global health governance system to ensure timely and equitable access to medicines and health

technologies for all. A global social contract is needed to align individual state interests and incentives for the pharmaceutical industry with the global goal of protecting public health and health security. A pandemic treaty could both be shaped by this need and help create the conditions for an effective global social contract for access to medicines and health technologies.

::::::

### **Transforming Health Crises with Pandemic Therapies**

CSIS Report

November 9, 2022 | Katherine E. Bliss, J. Stephen Morrison

A final report from the CSIS Commission on Strengthening America's Health Security's working group on Covid-19 therapies discusses how to strengthen U.S. leadership and global action to ensure development of, access to, and uptake of Covid-19 therapies worldwide.

PDF:

https://csis-website-prod.s3.amazonaws.com/s3fs-

<u>public/publication/221109 HealthCommission Covid19Therapies 0.pdf?txKGAAJd0kMUOFfc1mZVUbWl</u> OTF1s1jR

The CSIS Commission on Strengthening America's Health Security convened a working group on Covid-19 therapies in the fall of 2021 to develop policy recommendations aimed at strengthening U.S. leadership and global action to ensure development of, access to, and uptake of Covid-19 therapies worldwide.

Drawing on insights gleaned through private meetings and roundtable discussions with pharmaceutical manufacturers, government officials, representatives of multilateral organizations, and nongovernmental organizations, and building on points raised in an interim report published in July 2022, the working group recommends in this final report the following:

- 1. Continue research and development into a diverse set of treatment options, ensuring innovative therapeutic products are designed with the intent of reaching populations in high-, middle-, and low-income countries at the same time.
- 2. Accelerate U.S. leadership and diplomacy to mobilize adequate new resources for global distribution of Covid-19 therapies.
- 3. Prioritize the development of a global coordination mechanism to finance, scale, and monitor the international mobilization for Covid-19 therapies and future pandemic rapid response.
- 4. Intensify the focus on strengthening health systems, including greater emphasis on primary health care, to improve the capacity of health facilities and health workers to diagnose Covid-19 infections and deliver innovative Covid-19 therapies.
- 5. Accelerate the development of a comprehensive communications strategy to combat misinformation; provide accurate, independent, and accessible information; and improve patients' and providers' understanding of the uses and benefits of Covid-19 therapies...

WHO, WIPO, WTO to hold technical symposium on response, preparedness to future pandemics

10 November 2022

The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO will hold on 16 December 2022 a joint technical symposium on "COVID-19 Pandemic: Response, Preparedness, Resilience". The event will take place in hybrid form at WIPO headquarters.

The COVID-19 pandemic is an extraordinary global public health crisis involving a broad range of policy areas. Large-scale efforts since early 2020 to develop effective treatments, diagnostics and vaccines have resulted in the approval of the first vaccines in late 2020. These efforts have highlighted the urgent need for a response along the entire value chain of health technologies relating to COVID-19, ranging from research and development (R&D) of health technologies to their medical regulation, procurement, distribution and responsible use.

The objective of the Symposium is to examine key challenges of the COVID-19 pandemic within the frameworks of health, trade and intellectual property, and to discuss the way forward to build resilience to be better prepared for future pandemics. The event will be opened by the three Directors-General. The keynote address will be delivered by Salim Abdool Karim, Director of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and Professor for Global Health in the Department of Epidemiology at Columbia University, who will review developments during the pandemic and options for a way forward from a scientific perspective.

This will be followed by two panel discussions. During the first panel, speakers will share their respective experiences with regard to select key challenges faced during the COVID-19 pandemic, including R&D, scaling up and diversifying manufacturing, transfer of technology and know-how and equitable access to medical technologies. Speakers on the second panel will be invited to review initiatives to respond to and recover from the current health crisis and build resilience for future pandemics. The Symposium will be interactive and will offer a forum for all stakeholders to exchange views and experiences.

The Symposium is the ninth in a series of joint technical symposia convened by the WHO, WIPO and the WTO. It builds on the collaborative work undertaken by the three organizations to enhance capacity in their members to deal with issues at the intersections between health, trade and intellectual property, including the trilateral publication Promoting Access to Medical Technologies and Innovation. The publication and information about the previous symposia are available at <a href="https://www.wiposia.com/wiposia

Information about the draft programme, online registration and the live webcast will be available from the <a href="Symposium webpage">Symposium webpage</a>. Online registration is mandatory by 11 December 2022 at <a href="Webinar Registration">Webinar Registration</a> — Zoom.

.....

### **PHEIC**

### **Coronavirus [COVID-19] - WHO**


Public Health Emergency of International Concern (PHEIC) <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</a>

Weekly epidemiological update on COVID-19 - 9 November 2022

### Overview

Globally, the number of new weekly cases decreased by 15% during the week of 31 October to 6 November 2022, as compared to the previous week, with over 2.1 million new cases reported. The number of new weekly deaths decreased by 10%, as compared to the previous week, with about 9400 fatalities reported. As of 6 November 2022, 629 million confirmed cases and 6.5 million deaths have been reported globally.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 6 November 2022\*\*



::::::

### Weekly Epidemiological and Operational updates

Last update: 11 Nov 2022

 Confirmed cases ::
 630 832 131

 Confirmed deaths ::
 6 584 104

 Vaccine doses administered:
 12 861 382 558

::::::

<u>UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 12 Nov 2022</u>


An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]



### **Global Dashboard on COVID-19 Vaccine Equity**

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 12 Nov 2022]: <a href="https://data.undp.org/vaccine-equity/">https://data.undp.org/vaccine-equity/</a> See also visualization on <a href="Vaccine Access">Vaccine Access</a> and <a href="Vaccine Affordability">Vaccine Affordability</a>



### **COVID-19 Global Targets and Progress Tracker - IMF**

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, **a**nd delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

::::::

.....

::::::

**COVID Vaccines – OCHA:: HDX** 

### **COVID-19 Data Explorer: Global Humanitarian Operations**

COVID-19 Vaccine Roll-out

NOV 05 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 121M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 12.9B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 380M Other Delivered (Number of Doses): 400M Total Delivered (Number of Doses): 790M Total Administered (Number of Doses): 520M

::::::


### Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO] https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **12 Nov 2022**: <a href="https://data.covid19taskforce.com/data">https://data.covid19taskforce.com/data</a> The global view below is complemented by country-specific dashboards <a href="https://example.com/data">here</a>.






.....

### Duke – Launch and Scale Speedometer <a href="https://doi.org/10.2016/j.com/">The Race for Global COVID-19 Vaccine Equity</a>

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research



### Our World in Data

::::::

::::::

Coronavirus (COVID-19) Vaccinations [Accessed 12 Nov 2022]

- :: <u>68.2%</u> of the world population has received at least one dose of a COVID-19 vaccine.
- :: <u>12.94 billion doses</u> have been administered globally, and <u>2.59 million</u> are now administered each day.
- :: 23.6% of people in low-income countries have received at least one dose.

### **Global COVID-19 Access Tracker**

https://www.covid19globaltracker.org/



### U.S.: COVID-19/Vaccines - Announcements/Regulatory Actions/Deployment

#### HHS

::::::

<u>News</u>

No new digest content identified.

#### **FDA**

**Press Announcements** 

No new digest content identified.

::::::

**Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment** 

### **European Medicines Agency**

News & Press Releases

News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022 (new)

CHMP, Last updated: 11/11/2022

News: EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine (updated)

CHMP, Last updated: 11/11/2022

::::::

### **European Centre for Disease Prevention and Control**

https://www.ecdc.europa.eu/en

News [Selected]

### **Ebola outbreak in Uganda, as of 7 November 2022**

Epidemiological update - 11 Nov 2022

News

### **Weekly COVID-19 country overview**

Epidemiological update - 10 Nov 2022

News

### Joint ECDC-WHO/Europe monkeypox surveillance bulletin

Epidemiological update - 9 Nov 2022

News

### Monkeypox situation update, as of 8 November 2022

Epidemiological update - 9 Nov 2022

::::::

### Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

https://africacdc.org/covid-19-vaccination/



Russia: COVID-19 Vaccines - Announcements/Regulatory Actions/Deployment

Russia: Sputnik V - "the first registered COVID-19 vaccine"

https://sputnikvaccine.com/newsroom/pressreleases/

Press Releases

::::::

No new digest content	identified. Last press relea	ase issued 31.08.2022.		
:::::				
India: COVID-19 Vac	cines – Announcement	s/Regulatory Actions/De	eployment	
Ministry of Health an https://www.mohfw.go	<del>-</del>			
COVID-19 INDIA as on : 13 November 2022, 08:00 IST (GMT+5:30)	Active (0.03%)	Discharged (98.78%)	Deaths (1.19%)	
(↑↓ Status change since yesterday)	12307	44123539	530531	
COVID-19 Vaccination as on : 13 November 2022, 08:00 IST (GMT+5:30)	Total Vaccin	ation: 2,198,001,6	94 <b>(92,188 ^</b> )	
<u>Latest Press Releases</u> No new digest content	edical Research (ICMR) n/media.html			
:::::				
China: COVID-19 Vac	ccines – Announcemen	ts/Regulatory Actions/D	eployment	
	y substantive, official anno or other China locations.]	ouncements about China's C	OVID response in general	
:::::: ::::::				
_	cy of International Concern mergencies/situations/mor	•		
Last Situation Report da	ated 2 November 2022			
:::::				

# PHEIC Polio

::::::

### Polio this week as of 09 November 2022 - GPEI

Summary of new polioviruses this week:

- Afghanistan: two WPV1 positive environmental samples
- DR Congo: five cVDPV1 cases and eight cVDPV2 cases
- Mozambique: three cVDPV1 cases
- Zambia: one cVDPV2 positive environmental sample

::::::

### **UN OCHA – Current Emergencies**

Current Corporate Emergencies

#### Afghanistan

No new digest content identified.

### Northern Ethiopia

No new digest content identified.

### Somalia

No new digest content identified.

### **Ukraine**

No new digest content identified.

::::::

### WHO & Regional Offices [to 12 Nov 2022]

https://www.who.int/news

Selected News/Announcements/Statements

10 November 2022

Departmental news

WHO issues consolidated guide to running effective telemedicine services

10 November 2022 Departmental news

WHO, WIPO, WTO to hold technical symposium on response, preparedness to future pandemics

9 November 2022 News release

### WHO releases first data on global vaccine market since COVID-19

9 November 2022

Departmental news

Global meeting on strengthening public-private provider engagement calls for greater collaboration with all care providers to get the TB response back-on-track and to enhance accountability

8 November 2022 Departmental news

<u>Third Virtual cGMP Training Marathon has started: vaccine manufacturers and regulatory officers will run together toward the finish line</u>

7 November 2022 Departmental news

WHO, members of the World Health Professions Alliance sign new memorandum of understanding on health workforce priorities

::::::

### **WHO Regional Offices**

Selected Press Releases, Announcements

**WHO African Region** 

:: <u>In Benin, a new lease on life against COVID-19</u> 10 November 2022

### WHO Region of the Americas PAHO

:: 11 Nov 2022

### The number of people with diabetes in the Americas has more than tripled in three decades, PAHO report says

Washington D.C. 11 November 2022 (PAHO/WHO) – Growing rates of obesity, poor diets, and lack of physical activity, among other factors, have contributed to a more than three-fold increase in the number of adults living with diabetes in the Americas in the past 30 years according to a new report by the Pan American Health Organization (PAHO). The...

:: 9 Nov 2022

### <u>Collaboration essential to make promise of health a reality for everyone across the Americas</u>

Boston, 9 November 2022 (PAHO) – During the annual meeting of the American Public Health Association (APHA), the Deputy Director of the Pan American Health Organization (PAHO) Mary Lou Valdez underscored the need to make use of collective resources and expertise to tackle pervasive health disparities across the region. "For over a century, the...

:: 9 Nov 2022

### WHO releases first data on global vaccine market since COVID-19

9 November 2022 This is the first report to capture the implications of COVID-19 for vaccine markets. Despite progress in recent decades, global market vaccine dynamics are not fully conducive to the development, supply and access for vital vaccines for public health. Vaccines prioritized by WHO are not being developed or fully invested...

### **WHO South-East Asia Region SEARO**

No new digest content identified.

### **WHO European Region EURO**

:: 11 November 2022 News release

Knowledgeable patients - are we ready for them? World Diabetes Day 2022

:: 11 November 2022 Statement

**Statement - Strengthening health systems in Europe** 

:: 10 November 2022 News release

WHO promotes action on urgent mental health needs of Ukrainian refugees

:: 9 November 2022 News release

Building health leadership for the future through the Pan-European Leadership Academy

### **WHO Western Pacific Region**

No new digest content identified.

::::::

### **Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

10 November 2022 | Ebola disease caused by Sudan ebolavirus - Uganda

7 November 2022 | Cholera - Malawi

::::::

#### **New WHO Publications**

https://www.who.int/publications/i

Selected Titles

11 November 2022

Global leishmaniasis surveillance: 2021, assessing the impact of the COVID-19 pandemic

11 November 2022

The nutrition challenge: food system solutions

10 November 2022

<u>Asia-Pacific workshop on surveillance, prevention and control of zoonotic influenza- Paro,</u>
<u>Bhutan</u>

9 November 2022

**Consolidated telemedicine implementation guide** 

8 November 2022

WHO guiding principles for pathogen genome data sharing

4 November 2022

WHO Ukraine crisis response: September 2022 bulletin

	•	٠		
-		٠	-	
=				

### **CDC/ACIP [U.S.]** [to 12 Nov 2022]

http://www.cdc.gov/media/index.html

https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases

No new digest content identified.

::::::

### **ACIP Meetings**

Next ACIP Meeting
No 2022 meetings identified.

::::::

### MMWR Weekly: Current Volume (71)

November 11, 2022 / No. 45

PDF of this issue

- <u>Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of</u> <u>Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022</u>
- <u>COVID-19–Associated Hospitalizations Among U.S. Infants Aged <6 Months COVID-NET, 13</u> States, June 2021–August 2022
- <u>Epidemiologic Features of the Monkeypox Outbreak and the Public Health Response United States, May 17–October 6, 2022</u>
- <u>Notes from the Field: Outbreak of Ebola Virus Disease Caused by Sudan ebolavirus Uganda,</u> August—October 2022

::::::

### Coronavirus Disease 2019 (COVID-19)- CDC

Announcements/reports/data summaries.

::::::

Africa CDC [to 12 Nov 2022]

http://www.africacdc.org/

News

<u>Africa CDC Saving Lives and Livelihoods Initiative Expands Implementation in Southern</u>
Africa

11 November 2022

::::::

#### **China CDC**

http://www.chinacdc.cn/en/

### **National Health Commission of the People's Republic of China** [to 12 Nov 2022]

http://en.nhc.gov.cn/

News

### Chinese mainland reports 1,150 new local confirmed COVID-19 cases

2022-11-11

The Chinese mainland on Thursday reported 1,150 locally transmitted confirmed COVID-19 cases, the National Health Commission said Friday

### National Medical Products Administration – PRC [to 12 Nov 2022]

http://english.nmpa.gov.cn/

### Chinese mainland reports 1,150 new local confirmed COVID-19 cases

2022-11-11

The Chinese mainland on Thursday reported 1,150 locally transmitted confirmed COVID-19 cases, the National Health Commission said Friday

### **CCDC Weekly Reports: Current Volume (4)**

2022-11-11 / No. 45 ALZHEIMER'S DISEASE ISSUE

View PDF of this issue

<u>Preplanned Studies: Geographic Variation in Inpatient Care Utilization, Outcomes and Costs for Dementia Patients Aged 65 Years or Older — China, 2017–2019</u>

<u>Preplanned Studies: COVID-19 Stay-At-Home Orders and Older Adults' Cognitive Health — United States, June 2018–Feburary 2022</u>

<u>Preplanned Studies: Polypharmacy Among People Living with Dementia — Israel and 24 Countries in European Union, 2015–2019</u>

<u>Preplanned Studies: Early-Life Circumstances and Cross-Country Disparities in Cognition Among Older Populations — China, the US, and the EU, 2008–2018</u>

### **Organization Announcements**

### **Paul G. Allen Frontiers Group** [to 12 Nov 2022]

https://alleninstitute.org/news-press/

News

### **Lake Conferences**

November 9, 2022

Circuit Neuroscience Basel and the Allen Institute are pleased to announce the Lake Conferences aiming to provide stimulating forums to broad research communities in key developing areas of neuroscience.

### **BMGF - Gates Foundation** [to 12 Nov 2022]

https://www.gatesfoundation.org/ideas/media-center

Press Releases and Statements

Nov 07, 2022

Gates Foundation Calls for Bold and Immediate Action at COP27, Announces New Commitment to Meet the Climate Adaptation Needs of Smallholder Farmers

### **Bill & Melinda Gates Medical Research Institute** [to 12 Nov 2022]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people News: Articles and Publications

No new digest content identified.

**CARB-X** [to 12 Nov 2022]

https://carb-x.org/

News

No new digest content identified.

### **Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 12 Nov 2022]

https://centerforvaccineethicsandpolicv.net/

News/Analysis/Statements

- :: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
- :: <u>Informed Consent: A Monthly Review November 2022</u> is now posted here

### **CEPI – Coalition for Epidemic Preparedness Innovations** [to 12 Nov 2022]

http://cepi.net/

Latest News

### From SpillOver to Disease X: new AI collaboration aims to rank viral families with greatest pandemic threat

CEPI to provide US\$1.76 million to support application of AI to expand UC Davis' SpillOver database 09 Nov 2022

### <u>Climate change isn't just warming the planet, it's increasing spillover risks and pandemic</u> threats

Expert calls for more investment to prevent viral spillover at source to mitigate against pandemic threats

09 Nov 2022

### CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to12

Nov 2022]

https://cioms.ch/ News; Publications

No new digest content identified.

### DARPA - Defense Advanced Research Projects Agency [U.S.] [to 12 Nov 2022

https://www.darpa.mil/news

News

No new digest content identified.

### **Duke Global Health Innovation Center** [to 12 Nov 2022]

https://dukeghic.org/

Our Blog

No new digest content identified.

### **EDCTP** [to 12 Nov 2022]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials No new digest content identified.

### **Emory Vaccine Center** [to 12 Nov 2022]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

### **European Vaccine Initiative** [to 12 Nov 2022]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified

### **Evidence Aid** [to 12 Nov 2022]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

http://www.evidenceaid.org/

Emotional and psychological impacts on healthcare workers of disasters and other mass casualty events

Added November 11, 2022

### Health system governance in settings with conflict-affected populations

Added November 10, 2022

### Factors influencing hospital resilience

Added November 9, 2022

### <u>Infectious disease surveillance for refugees at borders and in destination countries</u>

Added November 8, 2022

### **Fondation Merieux** [to 12 Nov 2022]

http://www.fondation-merieux.org/

News, Events

No new digest content identified.

### **Gavi** [to 12 Nov 2022]

https://www.gavi.org/

News Releases

No new digest content identified.

### **GHIT Fund** [to 12 Nov 2022]

https://www.ghitfund.org/newsroom/press

Press Releases

November 11, 2022

**GHIT Fund Announces New Investments: A Total of 790 Million Yen for Product** 

**Development of Neglected Tropical Diseases** 

### **Global Fund** [to 12 Nov 2022]

https://www.theglobalfund.org/en/news/

News & Stories

No new digest content identified.

### **Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 12 Nov

2022]

https://www.glopid-r.org/news/

News

Press Room

No new digest content identified.

### **Hilleman Laboratories** [to 12 Nov 2022]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

### **HHMI - Howard Hughes Medical Institute** [to 12 Nov 2022]

https://www.hhmi.org/news

Press Room

No new digest content identified.

### **Human Vaccines Project** [to 12 Nov 2022]

http://www.humanvaccinesproject.org/

News IMMUNOME Report

Nov 10, 2022

### Kristen Jill Abboud: Introducing the Human Immunome Report

Why deciphering the mysteries of human immunity could usher in a new era of human health

**IAVI** [to 12 Nov 2022]

https://www.iavi.org/

Latest News

No new digest content identified.

ICRC [to 015 Oct 2022]

https://www.icrc.org/en/whats-new

What's New [Selected]

### The triple threat of climate change, conflict, and health emergencies: A deadly mix for the most vulnerable in fragile settings

Climate change is not a distant threat. It is already dramatically affecting vulnerable people across the globe.

04-11-2022 | News release

### **International Coalition of Medicines Regulatory Authorities [ICMRA]**

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

### **IFFIm**

http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

**IFRC** [to 12 Nov 2022]

http://media.ifrc.org/ifrc/news/press-releases/

Press Releases [Selected]

### <u>IFRC launches Global Climate Resilience Platform to support 500 million people on climate crisis frontlines</u>

09/11/2022 | Press release

... the International Federation of Red Cross and Red Crescent Societies (IFRC) is launching today its <u>Global Climate Resilience Platform</u> to increase the resilience of communities most vulnerable to the changing climate.

The new initiative aims to support 500 million people by raising at least CHF1 billion through a fiveyear global initiative focusing on early warning and anticipatory action, nature-based solutions, and safety nets and shock responsive social protection...

### **Institut Pasteur** [to 12 Nov 2022]

https://www.pasteur.fr/en/press-area

Press Documents

No new digest content identified.

### ISC / International Science Council [to 22 Oct 2022]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Current

No new digest content identified.

### **International Union of Immunological Societies (IUIS)**

https://iuis.org/

News/Events [Selected]

No new digest content identified.

### **IVAC** [to 12 Nov 2022]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

<u>World Pneumonia Day 2022: Restoring Coverage of Pneumococcal Conjugate Vaccines as a Priority</u>

**IVI** [to 12 Nov 2022]

http://www.ivi.int/

IVI News & Announcements

### Lemonex, IVI exchange MOU on joint vaccine development

November 10, 2022, SEOUL, Republic of Korea – The International Vaccine Institute (IVI) announced on November 10 it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development. IVI and Lemonex have agreed to join forces to introduce DegradaBALL® drug delivery

technology to the development of infectious disease vaccines and advance vaccine development by using IVI's extensive expertise in all areas of vaccine development.

Under the MOU, Lemonex and IVI will seek to contribute to global public health through research and development cooperation with the view to develop vaccines that respond to infectious viruses and cater to the needs of developing countries, and through joint projects to achieve common goals...

### **Johns Hopkins Center for Health Security** [to 12 Nov 2022]

https://www.centerforhealthsecurity.org/news/center-news/ Center News [Selected] No new digest content identified.

### MSF/Médecins Sans Frontières [to 12 Nov 2022]

http://www.msf.org/ Latest [Selected Announcements] Haemorrhagic fevers Face to face with Ebola in Uganda

Project Update 11 Nov 2022

### National Academy of Medicine - USA [to 12 Nov 2022]

https://nam.edu/programs/ News [Selected] No new digest content identified.

### National Academy of Sciences - USA [to 12 Nov 2022]

http://www.nasonline.org/news-and-multimedia/ News

No new digest content identified.

### National Vaccine Program Office - U.S. HHS [to 12 Nov 2022]

https://www.hhs.gov/vaccines/about/index.html Upcoming Meetings/Latest Updates No new digest content identified.

NIH [to 12 Nov 2022] http://www.nih.gov/

News Releases

### **Experimental cancer vaccine shows promise in animal studies**

November 10, 2022 — NIH researchers find IV administration improves tumor-fighting action

### NIH-funded researchers to begin study of intravenous iron treatment for post-pregnancy anemia

November 10, 2022 — Study to enroll participants in seven low- and middle-income countries.

### NIH names Dr. Joni L. Rutter director of the National Center for Advancing Translational Sciences

November 8, 2022 — Rutter will lead NIH efforts to speed translation of scientific discoveries into new treatments and other health interventions.

### **PATH** [to 12 Nov 2022]

https://www.path.org/media-center/ Press Releases No new digest content identified.

### **Rockefeller Foundation** [to12 Nov 2022]

https://www.rockefellerfoundation.org/ Selected Reports/Press Releases No new digest content identified.

### **Sabin Vaccine Institute** [to 12 Nov 2022]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

### **UNAIDS** [to 12 Nov 2022]

http://www.unaids.org/en Selected Press Releases/Reports/Statements No new digest content identified.

### **UNICEF** [to 22 Oct 2022]

https://www.unicef.org/media/press-releases

Press Releases, News Notes, Statements [Selected]
No new digest content identified.

### **Unitaid** [to 12 Nov 2022]

https://unitaid.org/ Featured News No new digest content identified.

### **Vaccine Equity Cooperative [nee Initiative]** [to 12 Nov 2022]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

### **Vaccination Acceptance & Demand Initiative [Sabin)** [to 12 Nov 2022]

https://www.vaccineacceptance.org/

Announcements, Blog

Blog

**Health for All Ages: Life-Course Immunization** 

November 11, 2022 by: Danielle Countryman

Generating Advocacy for Life-Course Immunization around the World

### Vaccine Confidence Project [to 12 Nov 2022]

http://www.vaccineconfidence.org/

News, Research and Reports

No new digest content identified.

### **Vaccine Education Center – Children's Hospital of Philadelphia** [to 12 Nov 2022]

http://www.chop.edu/centers-programs/vaccine-education-center

News

No new digest content identified.

### Wellcome Trust [to 12 Nov 2022]

https://wellcome.ac.uk/news

News. Opinion, Reports

No new digest content identified.

### The Wistar Institute [to22 Oct 2022]

https://www.wistar.org/news/press-releases

Media

No new digest content identified.

### **WFPHA: World Federation of Public Health Associations** [to 12 Nov 2022]

https://www.wfpha.org/

Latest News - Blog

<u>Statement on Protecting Ecosystems & Supporting Nature-based Solutions for Improved</u>
Public Health

Nov 11, 2022

Statement on Protecting Ecosystems & Supporting Nature-based Solutions for Improved Public Health

**World Bank** [to 015 Oct 2022]

http://www.worldbank.org/en/news/all

All News

New Dashboard to Track Food and Nutrition Security and Global Response

WASHINGTON/BERLIN, November 9, 2022 —The Global Alliance for Food Security (GAFS), jointly convened by the German Group of Seven (G7) Presidency and the World Bank Group, today launched the Global Food...

Date: November 09, 2022 Type: Press Release

### World Customs Organization – WCO [to 015 Oct 2022]

http://www.wcoomd.org/

Latest News

### **WCO Secretary General addresses the Global Development Network of researchers**

07 November 2022

...At the opening session, Dr. Mikuriya mentioned three areas of Customs research: digital transformation, border management in fragile and conflict-affected situations (fragile borders) and environmental issues..

### World Medical Association [WMA] [to 12 Nov 2022]

https://www.wma.net/news-press/press-releases/

Press Releases

### Violence Against Health Personnel in Iran Must Stop, says WMA

9th November 2022

An immediate and unconditional end to violence against health personnel in Iran has been called for by the World Medical Association.

In an <u>open letter to the President of Iran</u>, the WMA refers to the alarming rate of violence with reports of arrests, ill treatment and at least one physician killed by security forces...

### WHO, members of the World Health Professions Alliance sign new memorandum of understanding on health workforce priorities

8 November 2022 – Today, the World Health Organization (WHO) signed a memorandum of understanding with the five members of the World Health Professions Alliance (WHPA): FDI World Dental Federation (FDI), International Pharmaceutical Federation (FIP), International Council of Nurses (ICN), World Physiotherapy, and World Medical Association (WMA). Together these five organizations represent more than 41 million health professionals worldwide and assemble essential knowledge and experience from the key health professions in more than 130 countries.

Today's signing ceremony represents an historic event, bringing together the five global organizations representing the world's dentists, pharmacists, nurses, physiotherapists and physicians with WHO to enhance their joint collaboration on protecting and investing in the health workforce to provide safe, quality and equitable care in all settings...

### **World Organisation for Animal Health (OIE)** [to 12 Nov 2022]

https://www.oie.int/en/ Press Releases, Statements No new digest content identified.

WTO - World Trade Organisation [to12 Nov 2022]

http://www.wto.org/english/news e/news e.htm

WTO News and Events [Selected]

### WHO, WIPO, WTO to hold technical symposium on response, preparedness to future pandemics

10 November 2022

The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO will hold on 16 December 2022 a joint technical symposium on "COVID-19 Pandemic: Response, Preparedness, Resilience". The event will take place in hybrid form at WIPO headquarters.

::::::

### **ARM [Alliance for Regenerative Medicine]** [to 12 Nov 2022]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

**BIO** [to 12 Nov 2022]

https://www.bio.org/press-releases

Press Releases

No new digest content identified.

### **DCVMN – Developing Country Vaccine Manufacturers Network** [to 12 Nov 2022]

http://www.dcvmn.org/ News; Upcoming events No new digest content identified.

### **ICBA – International Council of Biotechnology Associations** [to 12 Nov 2022]

https://internationalbiotech.org/news/

News

No new digest content identified.

### **IFPMA** [to 12 Nov 2022]

http://www.ifpma.org/resources/news-releases/ Selected Press Releases, Statements, Publications No new digest content identified.

### **International Alliance of Patients' Organizations – IAPO** [to 12 Nov 2022]

https://www.iapo.org.uk/news/topic/6

Press and media [Selected]

No new digest content identified.

### **International Generic and Biosimilar Medicines Association [IGBA]**

https://www.igbamedicines.org/

News

Press Releases

No new digest content identified.

**PhRMA** [to 12 Nov 2022]

http://www.phrma.org/

Press Releases

No new digest content identified.

::::::

### **Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements**

#### **AstraZeneca**

<u>Press Releases</u> \_- No new digest announcements identified

### **Bharat Biotech**

<u>Press Releases</u> - No new digest announcements identified

### **BioCubaFarma** – Cuba

<u>Últimas Noticias</u> - Website not responding at inquiry

### **Biological E**

<u>News</u> - No new digest announcements identified

#### **BioNTech**

Press Releases

<u>BioNTech and Fosun Pharma Receive Emergency Use Authorization for Omicron-BA.4/BA.5</u>
<u>Adapted Bivalent Vaccine in Hong Kong and Special Import Authorization for Macau</u>
11 November 2022

<u>Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted</u>
<u>Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European</u>
Union

10 November 2022

### **Boehringer**

<u>Press Releases</u> - No new digest announcements identified

#### **CanSinoBIO**

<u>News</u> - Website not responding at inquiry

#### **CIGB**

<u>Latest News</u> - No new digest announcements identified

### Cinnagen

Recent News - No new digest announcements identified

### Clover Biopharmaceuticals - China

<u>News</u> - No new digest announcements identified

### **Curevac [Bayer Ag – Germany]**

<u>News</u> - No new digest announcements identified

### **Gamaleya National Center**

Latest News and Events - See Russia above.

#### **GSK**

Press releases for media

10 November 2022

Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission

- First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
- Strong immune response against all tested variants of concern
- Ready to supply for autumn and winter COVID-19 vaccination campaigns in Europe

### IMBCAMS, China

<u>Home</u> - Website not responding at inquiry

### Janssen/JNJ

<u>Press Releases</u> - No new digest announcements identified

#### Medicago

Media - No new digest announcements identified

### Merck

News releases

Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies

November 7, 2022

#### Moderna

<u>Press Releases</u> - No new digest announcements identified

### Nanogen

<u>News</u> - No new digest announcements identified

### **Novartis**

News

Media Release Nov 07, 2022

Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics

#### Novavax

Press Releases

Nov 9, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Authorized in the United Kingdom for Use as a Booster in Adults

Nov 8, 2022

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

#### **Pfizer**

Recent Press Releases

11.10.2022

<u>Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted</u>
<u>Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European</u>
Union

11.04.2022

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

#### R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

### **Sanofi Pasteur**

Press Releases -

November 10, 2022 Press releases

<u>Press Release: Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn®</u>
Beta approved by the European Commission

November 4, 2022 *Press releases* 

<u>Press Release: European Commission grants first approval worldwide of Beyfortus®</u> (nirsevimab) for prevention of RSV disease in infants

### **Serum Institute of India**

<u>NEWS & ANNOUNCEMENTS</u> - No new digest announcements identified

### Shifa Pharmed [Iran]

http://shafapharmed.com/ No news page identified.

### Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified

### **Sinovac**

Press Releases

### SINOVAC Donates 100,000 Doses of Hepatitis A Vaccines to Pakistan

2022/11/09

#### **SK Biosciences**

<u>Press Releases</u> - No new digest announcements identified

#### **Takeda**

<u>Newsroom</u> - No new digest announcements identified

#### Valneva

<u>Press Releases</u> - No new digest announcements identified

### **Vector State Research Centre of Viralogy and Biotechnology**

<u>Home</u> - Website not responding [404 error]

### WestVac Biopharma

<u>Media</u> - No new digest announcements identified

### Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] [No website identified]

### ::::::

### Contents [click to move among sections]

- :: Coronavirus [COVID-19] WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

### :::::::

### Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>

### **AJOB Empirical Bioethics**

Volume 13, 2022 Issue 4

### https://www.tandfonline.com/toc/uabr21/current

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 24, Number 11: E1029-1106 Nov 2022

https://journalofethics.ama-assn.org/issue/how-much-will-it-cost

#### How Much Will It Cost?

An honest answer to the question, How much will it cost? is what most people seeking price transparency in health care tend to be after. Yet, what health care costs you or your family, or even being given an opportunity to assess whether you can afford services, is not how price transparency in health care is defined by even the most dedicated, knowledgeable advocates. A 2014 report from a landmark task force of the Healthcare Financial Management Association, for example, states that what all patients deserve from health care price transparency is "accurate price estimates from a reliable source." If this is the best definition of price transparency that a well-intentioned, well-informed task force suggests the American public can expect, one might reasonably suspect that, without dramatic reforms to financial structures of US health care, an honest answer to the question, How much will it cost? might not even be possible in many cases. This theme issue investigates why this problem matters clinically and ethically to every stakeholder, rich or poor, in the US health care system.

From the Editor Nov 2022

### **Ethical Dimensions of Pricing Transparency**

Seth Scheetz, MD and Marshall H. Chin, MD, MPH

Accurate information about what health services will cost patients is often not available at key decision points, yet surprisingly high bills can undermine public trust in clinicians and organizations.

### **American Journal of Infection Control**

November 2022 Volume 50 Issue 1 1p1193-1280

http://www.ajicjournal.org/current

[New issue; No digest content identified]

### **American Journal of Preventive Medicine**

November 2022 Volume 63 Issue 5 p669-874

https://www.ajpmonline.org/current

Research Articles

### **COVID-19 Vaccination and Intent for Vaccination of Adults With Reported Medical**

### **Conditions**

Peng-jun Lu, et al.

Published online: June 26, 2022

p760-771

### <u>Influenza Vaccination Coverage Among Medicare Fee-for-Service Beneficiaries</u>

Yuping Tsai, et al. Published online: July 26, 2022

p790-799

**Excess Mortality in California by Education During the COVID-19 Pandemic** 

Yea-Hung Chen, et al.

Published online: July 26, 2022

p827-836 Open Access

Topics in Education

### Impact of a Virtual Reality Curriculum on Human Papillomavirus Vaccination: A Pilot Trial

Francis J. Real, et al.

Published online: June 28, 2022

p865-873

### **American Journal of Public Health**

November 2022 112(11)

http://ajph.aphapublications.org/toc/ajph/current

NOTES FROM THE FIELD

### <u>Strategies for Addressing Vaccine Hesitancy Within California State Prisons in 2021 and Beyond</u>

Immunization/Vaccines, COVID-19

Ilana R. Garcia-Grossman, Liz Gransee and Brie Williams

112(11), pp. 1543-1545

### <u>Mobile Health Services for COVID-19: Counseling, Testing, and Vaccination for Medically</u> Underserved Populations

Immunization/Vaccines, COVID-19, Public Health Practice, Community Health

Priya Sarin Gupta, Amir M. Mohareb, Christine Valdes, Christin Price, Margaret Jollife, Craig Regis, Nehal Munshi, Eddie Taborda, Miriam Lautenschlager, Anne Fox, Diane Hanscom, Gina Kruse, Regina LaRocque, Joseph Betancourt and Elsie M. Taveras

112(11), pp. 1556–1559

### Making Vaccines Equitably Available to All Persons in Pima County, Arizona, 2020–2021

Health Service Delivery, Immunization/Vaccines, COVID-19, Socioeconomic Factors
Theresa Cullen, Jennie Mullins, Crystal La Tour Rambaud, Pierce Lawlor and Mary V. Davis
112(11), pp. 1560–1563

COVID-19 & MONKEYPOX

### Monkeypox, After HIV/AIDS and COVID-19: Suggestions for Collective Action and a Public Health of Consequence, November 2022

Infections, Prevention, Lesbian/Gay/Bisexual/Transgender Persons, Other Infections, Global Health Stewart Landers, Farzana Kapadia and Daniel Tarantola 112(11), pp. 1564–1566

### From COVID-19 to Monkeypox: Unlearned Lessons for Black, Latino, and Other Men With HIV Who Have Sex With Men

Infections, COVID-19, Lesbian/Gay/Bisexual/Transgender Persons, Race/Ethnicity, Epidemiology, African Americans/Blacks

Carlos E. Rodriguez-Diaz, Jeffrey S. Crowley, Yaiomy Santiago-Rivera and Gregorio A. Millett 112(11), pp. 1567–1571

## <u>Lessons for Community-Based Scale-Up of Monkeypox Vaccination From Previous Disease</u> <u>Outbreaks Among Gay, Bisexual, and Other Men Who Have Sex With Men in the United</u> States

Prevention, Immunization/Vaccines, Lesbian/Gay/Bisexual/Transgender Persons, Community Health, History, Health Policy

Ian W. Holloway 112(11), pp. 1572–1575

### **Getting the Message Right: Nurses and Vaccine Hesitancy**

Immunization/Vaccines, COVID-19, Health Professionals Kristen R. Choi, Catherine C. Cohen and Katia J. Bruxvoort 112(11), pp. 1576–1578

### **Vaccine Hesitancies Across the World in the Era of COVID-19**

Immunization/Vaccines, COVID-19, Epidemiology Nina Emery, Adeline Dugerdil and Antoine Flahault 112(11), pp. 1579–1581

### <u>Characteristics Associated With a Previous COVID-19 Diagnosis, Vaccine Uptake, and Intention to Be Vaccinated Among Essential Workers in the US Household Pulse Survey</u>

Immunization/Vaccines, COVID-19

Andrea L. Steege, Sara E. Luckhaupt, Rebecca J. Guerin, Andrea H. Okun, Mei-Chuan Hung, Girija Syamlal, Peng-Jun Lu, Tammy A. Santibanez, Matthew R. Groenewold, Rachael Billock, James A. Singleton and Marie Haring Sweeney 112(11), pp. 1599–1610

#### 112(11), pp. 1555 1010

### <u>Trends in COVID-19 Vaccine Acceptance in Spain, September 2020–May 2021</u>

Prevention, COVID-19, Health Promotion, Epidemiology, Social Science María Teresa Beca-Martínez, María Romay-Barja, Alba Ayala, María Falcon-Romero, Carmen Rodríguez-Blázquez, Agustín Benito and Maria João Forjaz 112(11), pp. 1611–1619

### <u>COVID-19 Vaccine Uptake and Factors Affecting Hesitancy Among US Nurses, March–June</u> 2021

Occupational Health, Immunization/Vaccines, COVID-19, Health Professionals, Epidemiology Janet W. Rich-Edwards, Carissa M. Rocheleau, Ming Ding, Jennifer A. Hankins, Laura M. Katuska, Xenia Kumph, Andrea L. Steege, James M. Boiano and Christina C. Lawson 112(11), pp. 1620–1629

### **American Journal of Tropical Medicine and Hygiene**

Volume 107 (2022): Issue 4\_Suppl (Oct 2022)

https://www.aitmh.org/view/journals/tpmd/107/4 Suppl/tpmd.107.issue-4 Suppl.xml

International Centers of Excellence for Malaria Research (ICEMR): Achievements in the Last Decade

[Reviewed earlier]

#### **Annals of Internal Medicine**

October 2022 Volume 175, Issue 10 <a href="http://annals.org/aim/issue">http://annals.org/aim/issue</a> [Reviewed earlier]

# Artificial Intelligence - An International Journal

Volume 312 November 2022 <a href="https://www.sciencedirect.com/journal/artificial-intelligence/vol/312/suppl/C">https://www.sciencedirect.com/journal/artificial-intelligence/vol/312/suppl/C</a> [New issue; No digest content identified]

#### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 12 Nov 2022) [No new digest content identified]

#### **BMJ Global Health**

November 2022 - Volume 7 - 11 https://gh.bmj.com/content/7/11 Commentary

# <u>A global social contract to ensure access to essential medicines and health technologies</u> (11 November, 2022)

Katrina Perehudoff, Veronika J Wirtz, Anna Wong, Violet Rusu, Jillian Kohler *Summary box* 

- The COVID-19 pandemic illuminates the need to move away from the current social contract, which focuses on the nation-state's responsibility for protecting the health of its own population, including by providing essential medicines and health technologies.
- We argue for embracing a global social contract, which is a governance concept that lays the foundation for how states should act as members of the international community, as regulators of the private pharmaceutical industry and as guarantors of public goods benefiting people worldwide.
- A global social contract should be based on a set of four principles: collective state stewardship of the pharmaceutical and health technology; equity and the protection of health as a human right; an effective global polity; and governmental transparency and democratic accountability.
- This foundation can serve as a basis for a future pandemic treaty and as a model to address the much broader global crisis of inequitable access to medicines and health technologies for infectious and non-communicable diseases.

# <u>Influenza vaccination may have only minimum or no effect on COVID-19 in the aged population</u> (7 November, 2022)

Lan Yao, Carolyn Graff, Weikuan Gu, Dianjun Sun

#### Original research

<u>Global variations in the burden of SARS-CoV-2 infection and its outcomes in pregnant</u> <u>women by geographical region and country's income status: a meta-analysis</u> (11 November, 2022) Jameela Sheikh, Heidi Lawson, John Allotey, Magnus Yap, Rishab Balaji, Tania Kew, Elena Stallings, Dyuti Coomar, Andrea Gaetano-Gil, Javier Zamora, Shakila Thangaratinam

# <u>Shifting paradigm from biomedical to decolonised methods in Inuit public health research in Canada: a scoping review</u> (2 November, 2022)

Loubna Belaid, Richard Budgell, Caroline Sauvé, Neil Andersson

Practice

<u>Improving access to medicines: lessons from 10 years of drug reforms in China, 2009–2020</u> (4 November, 2022)

Wenhui Mao, Hongli Jiang, Elias Mossialos, Wen Chen

#### **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content (Accessed 12 Nov 2022)

<u>Patient satisfaction with pharmacist-administered COVID-19 vaccines in Poland: a survey study in the vaccination centres context</u>

Since 2021, pharmacists in Poland have been authorised to administer vaccinations against COVID-19, which is of particular significance in the efforts towards preventing the spread of the pandemic. The primary...

Authors: Piotr Merks, Anna Kowalczuk, Alexandre Wong, Kevin Chung, Urszula Religioni, Dariusz Świetlik, Katarzyna Rotmans-Plagens, Jameason Cameron, Katarina Fehir Sola, Justyna Kazmierczak, Eliza Blicharska, Regis Vaillancourt and Agnieszka Neumann-Podczaska

Citation: BMC Health Services Research 2022 22:1339

Content type: Research article Published on: 11 November 2022

# Examining oral pre-exposure prophylaxis (PrEP) literacy among participants in an HIV vaccine trial preparedness cohort study

PrEP literacy is influenced by many factors including the types of information available and how it is interpreted. The level of PrEP literacy may influence acceptability and uptake.

Authors: Rujeko Samanthia Chimukuche, Rachel Kawuma, Nteboheleng Mahapa, Smanga Mkhwanazi, Nishanta Singh, Samantha Siva, Eugene Ruzagira and Janet Seeley

Citation: BMC Health Services Research 2022 22:1336

Content type: Research Published on: 10 November 2022

#### Medical screening tests and vaccination among hospital-based physicians in Israel

Very few studies have evaluated physician participation in screening tests and vaccinations. The aim was to evaluate attitudes and actual practice of screening tests and vaccinations among hospital-based physi...

Authors: Sameeh Eltalakat, Berjas Abu Gariba, Roni Peleg, Daniel Kaplan and Yulia Treister-Gotzman

Citation: BMC Health Services Research 2022 22:1335 Content type: Research Published on: 10 November 2022

<u>Willingness to pay for HPV vaccine among female health care workers in a Chinese nationwide survey</u>

Payment methods for human papillomavirus (HPV) vaccine could substantially influence vaccination behavior. In China, HPV vaccination uptake remains currently low. This study aims to determine willingness to pa...

Authors: Xinyue Lu, Mengdi Ji, Abram L. Wagner, Weifeng Huang, Xiaoping Shao, Weiyu Zhou and

Yihan Lu

Citation: BMC Health Services Research 2022 22:1324 Content type: Research Published on: 5 November 2022

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content

(Accessed 12 Nov 2022)

<u>Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical</u> outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy

We aimed to assess harms (post-vaccine myocarditis and pericarditis) and benefits (preventing severe disease) of COVID-19 vaccination.

Authors: Giovanni Corrao, Matteo Franchi, Danilo Cereda, Francesco Bortolan, Olivia Leoni, Eugenio

Vignati, Giovanni Pavesi and Andrea Gori

Citation: BMC Infectious Diseases 2022 22:844

Content type: Research article Published on: 12 November 2022

# <u>Spatial distribution of rotavirus immunization coverage in Ethiopia: a geospatial analysis</u> using the Bayesian approach

Rotavirus causes substantial morbidity and mortality every year, particularly among under-five children. Despite Rotavirus immunization preventing severe diarrheal disease in children, the vaccination coverage...

Authors: Kendalem Asmare Atalell, Alemneh Mekuriaw Liyew and Kefyalew Addis Alene

Citation: BMC Infectious Diseases 2022 22:830

Content type: Research Published on: 9 November 2022

# SARS-Cov-2 incubation period according to vaccination status during the fifth COVID-19 wave in a tertiary-care center in Spain: a cohort study

The incubation period of an infectious disease is defined as the elapsed time between the exposure to the pathogen and the onset of symptoms. Although both the mRNA-based and the adenoviral vector-based vaccin...

Authors: Jordi Cortés Martínez, Daewoo Pak, Gabriela Abelenda-Alonso, Klaus Langohr, Jing Ning,

Alexander Rombauts, Mireia Colom, Yu Shen and Guadalupe Gómez Melis

Citation: BMC Infectious Diseases 2022 22:828

Content type: Research Published on: 9 November 2022

#### **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content (Accessed 12 Nov 2022) [No new digest content identified]

#### **BMC Medicine**

#### http://www.biomedcentral.com/bmcmed/content

(Accessed 12 Nov 2022)

[No new digest content identified]

# **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 12 Nov 2022) [No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles

(Accessed 12 Nov 2022)

Measles second dose vaccine utilization and associated factors among children aged 24–35 months in Sub-Saharan Africa, a multi-level analysis from recent DHS surveys

Although a safe and effective vaccine is available, measles remains an important cause of mortality and morbidity among young children in Sub-Saharan Africa (SSA). The WHO and UNICEF recommended measles-contai...

Authors: Dagmawi Chilot, Daniel Gashaneh Belay, Kegnie Shitu, Yibeltal Yismaw Gela, Mihret Getnet, Bezawit Mulat, Atalay Goshu Muluneh, Mehari Woldemariam Merid, Desalegn Anmut Bitew and Adugnaw Zeleke Alem

Citation: BMC Public Health 2022 22:2070

Content type: Research Published on: 12 November 2022

# <u>Changes in preventive behaviour after COVID-19 vaccination in Thailand: a cross-sectional</u> study

Protective behaviours (e.g., mask-wearing, handwashing, avoiding social gatherings) and mass vaccination are effective ways to control the coronavirus disease 2019 (COVID-19) pandemic. Previous studies found t...

Authors: Pitchayanont Ngamchaliew, Narathip Kaewkuea, Netipong Nonthasorn, Thanawat Vonnasrichan, Natthakarn Rongsawat, Leena Rattanachai, Wannachai Chaipipattanakij, Sutthida Kamolnawin and Polathep Vichitkunakorn

Citation: BMC Public Health 2022 22:2039

Content type: Research Published on: 8 November 2022

# Examining the relationships between trust in providers and information, mistrust, and COVID-19 vaccine concerns, necessity, and intentions

To facilitate maximum uptake of the COVID-19 vaccine, the roles of medical trust and mistrust of healthcare professionals must be examined. Previous work suggests that trust and mistrust may have differential ...

Authors: Lillie D. Williamson and Adati Tarfa Citation: BMC Public Health 2022 22:2033

Content type: Research Published on: 7 November 2022

<u>COVID-19 vaccine hesitancy and short-term and long-term intentions among unvaccinated young adults: a mixed-method approach</u>

Only 63.8% of Americans who are 18-to-24-years-old have been fully vaccinated for COVID-19 as of June 1, 2022. The Grand Forks County, North Dakota is facing a similar challenge. As of June 2022, 47% of indivi...

Authors: Soojung Kim, Erin Willis, Shane Wehlage, Hannah Scheffer-Wentz and Michael Dulitz

Citation: BMC Public Health 2022 22:2030

Content type: Research Published on: 7 November 2022

#### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 12 Nov 2022) [No new digest content identified]

#### **BMJ Evidence-Based Medicine**

October 2022 - Volume 27 - 5 https://ebm.bmj.com/content/27/5 [Reviewed earlier]

### **BMJ Open**

September 2022 - Volume 12 - 9 https://bmjopen.bmj.com/content/12/9 [Reviewed earlier]

# **Bulletin of the World Health Organization**

Volume 100(11); 2022 Nov 1

https://www.ncbi.nlm.nih.gov/pmc/issues/419724/

Systematic Reviews

# Scoping review of rehabilitation care models for post COVID-19 condition

Simon Décary, Wouter De Groote, Chiara Arienti, Carlotte Kiekens, Paolo Boldrini, Stefano Giuseppe Lazzarini, Michèle Dugas, Théo Stefan, Léa Langlois, Frédérique Daigle, Florian Naye, Annie LeBlanc, Stefano Negrini

Bull World Health Organ. 2022 Nov 1; 100(11): 676–688. Published online 2022 Oct 3.

doi: 10.2471/BLT.22.288105

PMCID: PMC9589389

#### **Perspectives**

### **Emergency preparedness and readiness; anticipating the need for rehabilitation**

Pete Skelton, Flavio Salio, Nedret Emiroglu

Bull World Health Organ. 2022 Nov 1; 100(11): 744-746. Published online 2022 Oct 3.

doi: 10.2471/BLT.22.289085

PMCID: PMC9589385

#### Health systems and policy research needed to strengthen the rehabilitation workforce

Jim Campbell, Jody-Anne Mills

Bull World Health Organ. 2022 Nov 1; 100(11): 747–748. Published online 2022 Oct 3.

doi: 10.2471/BLT.22.289032

PMCID: PMC9589379

#### Cell

Nov 10, 2022 Volume 185 Issue 23 p4249-4464

https://www.cell.com/cell/current

Leading edge

#### By their powers combined, global initiative joins forces for genomic research

Genevieve L. Wojcik

Genome-wide association studies (GWASs) can require immense sample sizes to identify variants associated with human health across the frequency spectrum. As the Global Biobank Meta-analysis Initiative (GBMI), Zhou et al. describe a collaborative network across 23 biobanks and 2.2 million participants to address challenges of underrepresentation of diversity in genomic research.

#### **Articles**

# <u>Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude</u> <u>and quality of antibody and B cell responses</u>

Clarisa M. Buckner, et al.

For COVID-19 mRNA vaccines, immunization with a booster dose elicits robust antibody and B cell responses that are further increased if a breakthrough infection occurs after vaccination. In contrast, when infection occurs prior to booster vaccination, antibody and B cell responses are muted closer to the infection time and achieve better levels as the time interval between infection and vaccination increases.

#### Resources

# <u>Genomic architecture of autism from comprehensive whole-genome sequence annotation</u> Brett Trost, et al.

The latest release of the Autism Speaks MSSNG resource provides an expanded sample size and facilitates the comprehensive examination of the roles of many types of genetic variation in autism spectrum disorder.

# **Child Care, Health and Development**

Volume 48, Issue 6 Pages: 881-1137 November 2022 <a href="https://onlinelibrary.wiley.com/toc/13652214/current">https://onlinelibrary.wiley.com/toc/13652214/current</a>

Special Issue: The Pervasive Effects of COVID-19 on Children: A Global Perspective

Issue Edited by: Jan Willian Gorter, Evelyn Culnane, Lyndal Hickey, Mark Ferro, Tony Okely

[Reviewed earlier]

#### **Clinical Pharmacology & Therapeutics**

Volume 112, Issue 5 Pages: 917-1130 November 2022 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

[New issue; No digest content identified]

# **Clinical Therapeutics**

September 2022 Volume 44 Issue 9 p1173-1268 <a href="http://www.clinicaltherapeutics.com/current">http://www.clinicaltherapeutics.com/current</a> [Reviewed earlier]

#### **Clinical Trials**

Volume 19 Issue 5, October 2022 https://journals.sagepub.com/toc/ctja/19/5 [Reviewed earlier]

#### **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 12 Nov 2022] [No new digest content identified]

### **Contemporary Clinical Trials**

Volume 122 November 2022

https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/122/suppl/C Short communication Abstract only

# <u>Machine learning for detecting centre-level irregularities in randomized controlled trials: A</u> pilot study

Jeremy Petch, Walter Nelson, Shuang Di, Kumar Balasubramanian, ... Shrikant I. Bangdiwala Article 106963

Research article Abstract only

# Economic analysis of a single institutional review board data exchange standard in multisite clinical studies

Eric L. Eisenstein, Anita Walden, Katrina Donovan, Meredith N. Zozus, ... Lawrence H. Muhlbaier Article 106953

Research article Open access

# <u>Cognitive rehabilitation in post-COVID-19 condition: A study protocol for a randomized</u> controlled trial

Bjørn Ingulfsvann Hagen, Anners Lerdal, Arne Søraas, Nils Inge Landrø, ... Jan Stubberud Article 106955

#### The CRISPR Journal

Volume 5, Issue 5 / October 2022 https://www.liebertpub.com/toc/crispr/5/5 [Reviewed earlier]

#### **Current Genetic Medicine Reports**

Volume 10, issue 1, March 2022

https://link.springer.com/journal/40142/volumes-and-issues/10-1

[Reviewed earlier]

# **Current Opinion in Infectious Diseases**

December 2022 - Volume 35 - Issue 6

https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx

[New issue; No digest content identified]

#### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020 <a href="https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current">https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current</a> [Reviewed earlier]

# **Developing World Bioethics**

Volume 22, Issue 3 Pages: 123-180 September 2022 <a href="https://onlinelibrary.wiley.com/toc/14718847/current">https://onlinelibrary.wiley.com/toc/14718847/current</a> [Reviewed earlier]

# **Development in Practice**

Volume 32, Issue 8, 2022 http://www.tandfonline.com/toc/cdip20/current [Reviewed earlier]

#### **Disaster Medicine and Public Health Preparedness**

Volume 16 - Issue 5 - October 2022

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

[Reviewed earlier]

#### **Disasters**

Volume 46, Issue 4 Pages: 853-1126 October 2022 <a href="https://onlinelibrary.wiley.com/toc/14677717/current">https://onlinelibrary.wiley.com/toc/14677717/current</a> [Reviewed earlier]

#### **EMBO Reports**

Volume 23 Issue 11 7 November 2022

https://www.embopress.org/toc/14693178/current

Science & Society 10 October 2022

<u>Limiting hESC patents in China under a dual-value perspective: Chinese patent law has several tools available to avoid patent thickets and patent monopolization</u>

Wei Zhang, Jiajv Chen, Wei Li

Limited rights, open licenses, and compulsory licenses are measures to ensure that hESCs-related patents are optimally used to promote scientific research and economic and social development.

# **Emerging Infectious Diseases**

Volume 28, Number 10—October 2022 <a href="http://wwwnc.cdc.gov/eid/">http://wwwnc.cdc.gov/eid/</a> [Reviewed earlier]

### **Epidemics**

Volume 40 September 2022 <a href="https://www.sciencedirect.com/journal/epidemics/vol/40/suppl/C">https://www.sciencedirect.com/journal/epidemics/vol/40/suppl/C</a> [Reviewed earlier]

# **Epidemiology and Infection**

Volume 150 - 2022 <a href="https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue">https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue</a> [Reviewed earlier]

#### **Ethics & Human Research**

Volume 44, Issue 6 Pages: 1-42 November—December 2022 https://onlinelibrary.wiley.com/toc/25782363/current

**Alzheimer disease biomarkers :: Payment to participate**Articles

#### Participants' Perspectives on Payment for Research Participation: A Qualitative Study

Emily A. Largent, Whitney Eriksen, Frances K. Barg, S. Ryan Greysen, Scott D. Halpern

Pages: 14-22

First Published: 31 October 2022

Essay

#### **Is Russia's Research Ethics Culture Reliable?**

Sergio G. Litewka, Jonathan D. Moreno

Pages: 39-42

First Published: 13 September 2022

#### **Ethics & International Affairs**

Spring 2022 (36.1) | March 10, 2022 https://www.ethicsandinternationalaffairs.org/2022/spring-2022-36-1/ [Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 24 October 2022

https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/24/suppl/C

#### [Reviewed earlier]

# The European Journal of Public Health

Volume 32, Issue 5, October 2022 <a href="https://academic.oup.com/eurpub/issue/32/5">https://academic.oup.com/eurpub/issue/32/5</a> [Reviewed earlier]

# **Expert Review of Vaccines**

Vol 21 (11) 2022 <a href="https://www.tandfonline.com/toc/ierv20/current">https://www.tandfonline.com/toc/ierv20/current</a> [Reviewed earlier]

# **Foreign Affairs**

Volume 101, Number 5 September/October 2022 <a href="https://www.foreignaffairs.com/issues/2022/101/5">https://www.foreignaffairs.com/issues/2022/101/5</a> [Reviewed earlier]

# **Forum for Development Studies**

Volume 49, 2022 - Issue 3 <a href="http://www.tandfonline.com/toc/sfds20/current">http://www.tandfonline.com/toc/sfds20/current</a> [Reviewed earlier]

#### **Genetics in Medicines**

Volume 24, Issue 11 Pages A1-A8, 2211-2418 (November 2022) https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/11 Editorial Full text access

Considerations for policymakers for improving health care through telegenetics: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG) Heather E. Williams, Lila Aiyar, Mary Beth Dinulos, David Flannery, ... David Viskochil Pages 2211-2219

**Excerpt** 

Telegenetics, a form of telemedicine, is 2-way, interactive real-time electronic information communication between a patient and genetics health care professional(s) (ie, medical geneticists [physicians who specialize in genetics] and genetic counselors [health care workers with training in medical genetics and counseling]) as an alternate to providing health care in person at a medical office. 1,2 These services include, but are not limited to, assessment, diagnosis, consultation, test result release, education, counseling, management of care, and/or aided self-management. In general, genetics services do not require immediate physical intervention, which makes the provision of these services well suited to telemedicine. This statement is intended to assist policymakers in gaining familiarity with the current state of genetics services provided via telehealth...

#### **Genome Medicine**

#### https://genomemedicine.biomedcentral.com/articles

[Accessed 12 Nov 2022]

[No new digest content identified]

#### **Global Health Action**

Volume 15, Issue 1 (2022)

https://www.tandfonline.com/toc/zgha20/current?nav=tocList

[Reviewed earlier]

# **Global Health: Science and Practice (GHSP)**

Vol. 10, No. 5 October 31, 2022 <a href="http://www.ghspjournal.org/content/current">http://www.ghspjournal.org/content/current</a> [Reviewed earlier]

# Global Legal Monitor – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/

[Accessed 12 Nov 2022]

[No new digest content identified]

#### **Global Public Health**

Volume 17, Issue 10 (2022)

http://www.tandfonline.com/toc/rgph20/current

# (Re)imagining Research, Activism, and Rights at the Intersections of Sexuality, Health, and Social Justice

[Reviewed earlier]

#### **Globalization and Health**

http://www.globalizationandhealth.com/ [Accessed 12 Nov 2022] [No new digest content identified]

### **Health and Human Rights**

Volume 24, Issue 1, June 2022 <a href="https://www.hhrjournal.org/volume-24-issue-1-june-2022/">https://www.hhrjournal.org/volume-24-issue-1-june-2022/</a> [Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 17 - Issue 4 - October 2022

https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

# **Health Policy and Planning**

Volume 37, Issue 9, November 2022 https://academic.oup.com/heapol/issue/37/9 ORIGINAL ARTICLES

To trust or not to trust: an exploratory qualitative study of personal and community perceptions of vaccines amongst a group of young community healthcare workers in Soweto, South Africa

<u>Jennifer Watermeyer</u>, <u>Megan Scott</u>, <u>Lethu Kapueja</u>, <u>Lisa Jayne Ware</u> Health Policy and Planning, Volume 37, Issue 9, November 2022, Pages 1167–1176, https://doi.org/10.1093/heapol/czac060

#### **REVIEW**

# The impacts of donor transitions on health systems in middle-income countries: a scoping review

<u>Hanna E Huffstetler</u>, <u>Shashika Bandara</u>, <u>Ipchita Bharali</u>, <u>Kaci Kennedy Mcdade</u>, <u>Wenhui Mao</u> ... Health Policy and Planning, Volume 37, Issue 9, November 2022, Pages 1188–1202, <u>https://doi.org/10.1093/heapol/czac063</u>

### **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 12 Nov 2022] [No new digest content identified]

#### **Human Gene Therapy**

Volume 33, Issue 19-20 / October 2022 https://www.liebertpub.com/toc/hum/33/19-20 [Reviewed earlier]

#### **Humanitarian Practice Network**

https://odihpn.org/ Featured Publications [No new digest content identified]

# **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 18, Issue 5, 2022 <a href="https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList">https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList</a> [Reviewed earlier]

# **Immunity**

Nov 08, 2022 Volume 5 5Issue 11 p1967-2210 https://www.cell.com/immunity/current Review

### **Innate immune mechanisms of mRNA vaccines**

Rein Verbeke, Michael J. Hogan, Karin Loré, Norbert Pardi

Lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccines produce adaptive immune responses protective against COVID-19. Here, Pardi and colleagues review the innate immune-sensing pathways of this vaccine modality and discuss research directions that may yield a next generation of mRNA vaccines with improved immunogenicity and reduced reactogenicity.

# **Infectious Agents and Cancer**

http://www.infectagentscancer.com/ [Accessed 12 Nov 2022] [No new digest content identified]

### **Infectious Diseases of Poverty**

http://www.idpjournal.com/content [Accessed 12 Nov 2022] [No new digest content identified]

#### **International Health**

Volume 14, Issue 6, November 2022 <a href="https://academic.oup.com/inthealth/issue/14/6">https://academic.oup.com/inthealth/issue/14/6</a> [Reviewed earlier]

# **International Human Rights Law Review**

Volume 11 (2022): Issue 1 (Jun 2022) https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml Table of Contents [Reviewed earlier]

#### **International Journal of Community Medicine and Public Health**

Vol 9, No 11 (2022) November 2022 <a href="https://www.ijcmph.com/index.php/ijcmph/issue/view/94">https://www.ijcmph.com/index.php/ijcmph/issue/view/94</a> [New issue; No digest content identified]

#### **International Journal of Epidemiology**

Volume 51, Issue 5, October 2022 <a href="https://academic.oup.com/ije/issue">https://academic.oup.com/ije/issue</a> [Reviewed earlier]

# **International Journal of Human Rights in Healthcare**

Volume 15 Issue 3, 2022

https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3

# **Special Issue: Children, young people and their international human right to healthcare** [Reviewed earlier]

#### **JAMA**

free access

November 8, 2022, Vol 328, No. 18, Pages 1793-1879 https://jamanetwork.com/journals/jama/currentissue Viewpoint

Addressing Gaps in Research to Reduce Disparities and Advance Health EquityThe USPSTF Incorporation of the NASEM Taxonomy on Closing Evidence Gaps in Clinical Prevention Carol M. Mangione, MD, MSPH; Wanda Nicholson, MD, MPH; Karina W. Davidson, PhD, MASC

JAMA. 2022;328(18):1803-1804. doi:10.1001/jama.2022.19154

This Viewpoint reviews the evidence gaps reported to Congress by the US Preventive Services Task Force (USPSTF) in 2021 on improving health inequities in prevention and uses the 3 taxonomies provided by National Academies of Sciences, Engineering, and Medicine (NASEM) to classify these gaps.

# Reforming the World Health Organization's Essential Medicines List-Essential but Unaffordable

Thomas J. Hwang, MD; Aaron S. Kesselheim, MD, JD, MPH; Kerstin N. Vokinger, MD, JD, PhD free access

JAMA. 2022;328(18):1807-1808. doi:10.1001/jama.2022.19459

This Viewpoint proposes restructuring the WHO Essential Medicines List to remove consideration of cost and cost-effectiveness from the expert committee reviews of clinical effectiveness, safety, and public health value, and chartering a new framework for pooled global negotiation and procurement of costly medicines included in the list.

#### **JAMA Pediatrics**

November 2022, Vol 176, No. 11, Pages 1061-1156 https://jamanetwork.com/journals/jamapediatrics/currentissue

**Viewpoint** 

# A Bill of Children's Digital Rights Is Required to Improve and Sustain Children's Futures Globally

Andres Roman-Urrestarazu, MD, PhD; Jane Kinsey, BPhty; Robin van Kessel, PhD JAMA Pediatr. 2022;176(11):1064-1066. doi:10.1001/jamapediatrics.2022.3418

This Viewpoint calls for policy action, such as a comprehensive Bill of Children's Digital Rights, that would embrace rights allowing children and young people to access the digital infrastructure and interact with digital media safely.

Editorial

Immune Response to SARS-CoV-2 Infection in Children

C. Mary Healy, MD

Original Investigation

<u>Peripartum Outcomes Associated With COVID-19 Vaccination During PregnancyA</u>
<u>Systematic Review and Meta-analysis</u>

Atsuyuki Watanabe, MD; Jun Yasuhara, MD; Masao Iwagami, MD, PhD; et al. free access has active quiz JAMA Pediatr. 2022;176(11):1098-1106. doi:10.1001/jamapediatrics.2022.3456

This study evaluates the association between COVID-19 vaccination during pregnancy and peripartum

#### **JBI Evidence Synthesis**

October 2022 - Volume 20 - Issue 10 <a href="https://journals.lww.com/jbisrir/Pages/currenttoc.aspx">https://journals.lww.com/jbisrir/Pages/currenttoc.aspx</a> [Reviewed earlier]

#### **Journal of Adolescent Health**

November 2022 Volume 71 Issue 5 p521-654 <a href="https://www.jahonline.org/current">https://www.jahonline.org/current</a> [New issue; No relevant content identified]

# **Journal of Artificial Intelligence Research**

Vol. 75 (2022) https://www.jair.org/index.php/jair Contents [Reviewed earlier]

#### **Journal of Community Health**

Volume 47, issue 6, December 2022 <a href="https://link.springer.com/journal/10900/volumes-and-issues/47-6">https://link.springer.com/journal/10900/volumes-and-issues/47-6</a> [New issue; No relevant content identified]

#### **Journal of Development Economics**

Volume 158 September 2022 <a href="https://www.sciencedirect.com/journal/journal-of-development-economics/vol/158/suppl/C">https://www.sciencedirect.com/journal/journal-of-development-economics/vol/158/suppl/C</a> [Reviewed earlier]

# **Journal of Empirical Research on Human Research Ethics**

Volume 17 Issue 4, October 2022 <a href="http://journals.sagepub.com/toc/jre/current">http://journals.sagepub.com/toc/jre/current</a> [Reviewed earlier]

#### **Journal of Epidemiology & Community Health**

October 2022 - Volume 76 - 10 https://jech.bmj.com/content/76/10 [Reviewed earlier]

#### **Journal of Evidence-Based Medicine**

Volume 15, Issue 3 Pages: 181-314 September 2022 <a href="https://onlinelibrary.wiley.com/toc/17565391/current">https://onlinelibrary.wiley.com/toc/17565391/current</a> [Reviewed earlier]

#### **Journal of Global Ethics**

Volume 18, Issue 1, 2022

http://www.tandfonline.com/toc/rjge20/current

**Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications**Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn

[Reviewed earlier]

# **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 33, Number 3, August 2022 https://muse.jhu.edu/issue/48370 Table of Contents [Reviewed earlier]

# **Journal of Immigrant and Minority Health**

Volume 24, issue 5, October 2022 https://link.springer.com/journal/10903/volumes-and-issues/24-5 Contents [Reviewed earlier]

#### **Journal of Immigrant & Refugee Studies**

Volume 20, 2022 \_ Issue 4 https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

#### **Journal of Infectious Diseases**

Volume 226, Issue 7, 1 October 2022 <a href="https://academic.oup.com/jid/issue/226/7">https://academic.oup.com/jid/issue/226/7</a> [Reviewed earlier]

#### **Journal of International Development**

Volume 34, Issue 7 Pages: 1257-1452 October 2022 <a href="https://onlinelibrary.wiley.com/toc/10991328/current">https://onlinelibrary.wiley.com/toc/10991328/current</a> [Reviewed earlier]

#### **Journal of Medical Ethics**

November 2022 - Volume 48 - 11 http://jme.bmj.com/content/current Extended essav

# Randomised controlled trials in medical AI: ethical considerations

Thomas Grote

**Abstract** 

In recent years, there has been a surge of high-profile publications on applications of artificial intelligence (AI) systems for medical diagnosis and prognosis. While AI provides various opportunities for medical practice, there is an emerging consensus that the existing studies show considerable deficits and are unable to establish the clinical benefit of AI systems. Hence, the view that the clinical benefit of AI systems needs to be studied in clinical trials—particularly randomised controlled trials (RCTs)—is gaining ground. However, an issue that has been overlooked so far in the debate is that, compared with drug RCTs, AI RCTs require methodological adjustments, which entail ethical challenges. This paper sets out to develop a systematic account of the ethics of AI RCTs by focusing on the moral principles of clinical equipoise, informed consent and fairness. This way, the objective is to animate further debate on the (research) ethics of medical AI.

### **Journal of Patient-Centered Research and Reviews**

Volume 9, Issue 3 (2022) <a href="https://institutionalrepository.aah.org/jpcrr/">https://institutionalrepository.aah.org/jpcrr/</a>
[Reviewed earlier]

#### **Journal of Pediatrics**

November 2022 Volume 250 p1-118 http://www.jpeds.com/current

Original Articles

# Revaccination and Adverse Event Recurrence in Patients with Adverse Events following Immunization

Caroline E. Muñoz, et al. on behalf of the Canadian Immunization Research Network Investigators Published online: August 23, 2022

p45-53.e3 Open Access

#### **Journal of Pharmaceutical Policy and Practice**

https://joppp.biomedcentral.com/

[Accessed 12 Nov 2022]

# Readiness and willingness of Malaysian community pharmacists in providing vaccination services

Vaccination is an effective public health intervention in reducing morbidity and mortality of infectious diseases. Compared to other countries where community pharmacists (CPs) administer vaccines, CPs in Mala...

Authors: Wei Chern Ang, Mohamad Syafuan Fadzil, Fatin Najihah Ishak, Nassrah Norissya Adenan and

Mohamad Haniki Nik Mohamed

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:81

Content type: Research Published on: 12 November 2022

# **Journal of Public Health Management & Practice**

November/December 2022 - Volume 28 - Issue 6

https://journals.lww.com/jphmp/pages/currenttoc.aspx

**Commentaries** 

### **Disciplining Physicians Who Spread Medical Misinformation**

Yang, Y. Tony; Schaffer DeRoo, Sarah

Journal of Public Health Management and Practice. 28(6):595-598, November/December 2022.

### Research Reports

# <u>COVID-19 Vaccine Uptake in Southeastern Ontario, Canada: Monitoring and Addressing</u> Health Inequities

Carter, Megan A.; Biro, Suzanne; Maier, Allison; More

Journal of Public Health Management and Practice. 28(6):615-623, November/December 2022.

# <u>Assessment of the Costs of Implementing COVID-19 Vaccination Clinics in 34 Sites, United</u> States, March 2021

Yarnoff, Benjamin O.; Pike, Jamison J.; Athar, Heba M.; More

Journal of Public Health Management and Practice. 28(6):624-630, November/December 2022.

# <u>COVID-19 Vaccine Knowledge, Attitudes, and Practices in Alabama: The Case for Primary</u> Health Care Providers

Bassler, John R.; Redden, David T.; Hall, Allyson G.; More

Journal of Public Health Management and Practice. 28(6):631-638, November/December 2022.

# COVID-19 Vaccine Acceptability Among People Experiencing Homelessness in Central Florida and Southern Nevada, March-June 2021

Meehan, Ashley A.; Aarvig, Kathleen; Kashani, Mitra; More

Journal of Public Health Management and Practice. 28(6):693-701, November/December 2022.

# Addressing Health Equity Goals for COVID-19 Vaccination Using Integrated Data and Mapping Tools: A Collaboration Between Academia, Public Health, and Health Care Systems in Columbus and Franklin County, Ohio

Hyder, Ayaz; Graffagnino, Cheryl; Barbeau, Rebecca; More

Journal of Public Health Management and Practice. 28(6):739-748, November/December 2022.

#### **Journal of Public Health Policy**

Volume 43, issue 3, September 2022

https://link.springer.com/journal/41271/volumes-and-issues/43-3

[Reviewed earlier]

# **Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

https://ir.library.louisville.edu/rgh/

#### [Reviewed earlier]

# **Journal of the Royal Society – Interface**

November 2022 Volume 19 Issue 196 https://royalsocietypublishing.org/toc/rsif/current [New issue; No digest content identified]

#### **Journal of Travel Medicine**

Volume 29, Issue 7, October 2022 <a href="https://academic.oup.com/jtm/issue">https://academic.oup.com/jtm/issue</a> [Reviewed earlier]

# **Journal of Virology**

Volume 96 Number 18 September 2022 <a href="http://jvi.asm.org/content/current">http://jvi.asm.org/content/current</a> [Reviewed earlier]

#### The Lancet

Nov 05, 2022 Volume 400 Number 10363 p1557-1654 https://www.thelancet.com/journals/lancet/issue/current Comment

<u>Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption</u>

Kevin Messacar, et al.

#### The Lancet Child & Adolescent Health

Nov 2022 Volume 6 Number 11 p747-828, e22-e23 https://www.thelancet.com/journals/lanchi/issue/current Comment

The monkeypox outbreak: risks to children and pregnant women Manon Vouga, et al.

Articles

Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019

Jing Zhang, et al.

Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study

Ian Kracalik, et al. for the Myocarditis Outcomes After mRNA COVID-19 Vaccination Investigators and the CDC COVID-19 Response Team

### **Lancet Digital Health**

Nov 2022 Volume 4Number 11 e765-e849

https://www.thelancet.com/journals/landig/issue/current

Comment

**Data solidarity: a blueprint for governing health futures** 

Barbara Prainsack, et al.

#### **Lancet Global Health**

Nov 2022 Volume 10 Number 11 e1534-e1687

https://www.thelancet.com/journals/langlo/issue/current

Editorial

# **Decision making in global health: is everyone on board?**

The Lancet Global Health

... All organisations involved in global health (including for-profit organisations) should have boards that are representative of the groups they serve, they should be publicly listed so they can be scrutinised, and these organisations should publish strategies on how they are addressing and aiming to resolve questions of board diversity, with time-bound targets. A representative board is unlikely to instantly realign an organisation's aims to perfectly concur with those of the disadvantaged but, providing these are not token appointments, would still be a valuable step.

Before and during the COVID-19 pandemic, NGOs such as the Gates Foundation filled a void created by the deficit of preparedness and initiative shown by many national governments. As nations, such as the UK, continue to cut international aid budgets and turn their increasingly myopic gaze inward, the importance of such NGOs will only grow in all facets of global health, not just the COVID-19 pandemic. This increased importance will have to come with increased scrutiny, as NGOs impact greater and greater numbers of people. And if an organisation truly aims to aid a traditionally underserved community, members of that community should be involved in the decision-making process at the very top.

#### Articles

<u>Prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic: a modelling study</u>
Sheikh Taslim Ali, et al.

<u>Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018–2020</u>

Manoj V Murhekar, et al.

Health Policy

<u>Pandemic preparedness and response: exploring the role of universal health coverage within the global health security architecture</u>

Arush Lal, et al.

Robustness of evidence reported in preprints during peer review Lindsay Nelson, et al.

#### **Lancet Infectious Diseases**

Nov 2022 Volume 22 Number 11 p1513-1648, e310-e347 https://www.thelancet.com/journals/laninf/issue/current

Editorial

**Ebola returns: back to square one** 

The Lancet Infectious Diseases

**Articles** 

<u>Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS)</u> <u>network cohort study</u>

Manish Sadarangani, et al. for the Canadian Immunization Research Network

<u>Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2</u> recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M Mallory, et al. on behalf of the Novavax 2019nCoV101 Study Group

<u>Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study</u>
Pilar T V Florentino, et al.

<u>Head-to-head comparison of the immunogenicity of RotaTeq and Rotarix rotavirus</u>
<u>vaccines and factors associated with seroresponse in infants in Bangladesh: a randomised, controlled, open-label, parallel, phase 4 trial</u>

Daniel E Velasquez-Portocarrero, et al.

Review

**Monoclonal antibody therapies against SARS-CoV-2** 

Daniele Focosi, et al.

Review of 2022 WHO guidelines on the control and elimination of schistosomiasis
Nathan C Lo, et al.

### **Lancet Public Health**

Nov 2022 Volume 7 Number 11 e885-e982

https://www.thelancet.com/journals/lanpub/issue/current

Articles

Association between influenza vaccination and risk of stroke in Alberta, Canada: a population-based study

Jessalyn K Holodinsky, et al.

<u>Association between influenza vaccination and risk of stroke in Alberta, Canada: a population-based study</u>

Jessalyn K Holodinsky, et al.

Review

# **COVID-19 mortality and deprivation: pandemic, syndemic, and endemic health inequalities**

Victoria J McGowan, Clare Bambra

Summary

COVID-19 has exacerbated endemic health inequalities resulting in a syndemic pandemic of higher mortality and morbidity rates among the most socially disadvantaged. We did a scoping review to identify and synthesise published evidence on geographical inequalities in COVID-19 mortality rates globally. We included peer-reviewed studies, from any country, written in English that showed any area-level (eg, neighbourhood, town, city, municipality, or region) inequalities in mortality by socioeconomic deprivation (ie, measured via indices of multiple deprivation: the percentage of people living in poverty or proxy factors including the Gini coefficient, employment rates, or housing tenure). 95 papers from five WHO global regions were included in the final synthesis. A large majority of the studies (n=86) found that COVID-19 mortality rates were higher in areas of socioeconomic disadvantage than in affluent areas. The subsequent discussion reflects on how the unequal nature of the pandemic has resulted from a syndemic of COVID-19 and endemic inequalities in chronic disease burden.

Conclusion

This Review has found extensive evidence of inequalities in COVID-19 mortality rates by area-level deprivation across the world. The pandemic has been an unequal experience with high mortality rates in the most deprived places and communities. These inequalities can be understood as a syndemic, arising from endemic inequalities in the social determinants of health. Reducing these inequalities—and those that might arise from future pandemics—requires long-term action to reduce inequalities in health and wealth. Future research and data collection should focus on improving surveillance systems by, for example, integrating measures of inequalities into the WHO Mortality Database.

#### **Lancet Respiratory Medicine**

Nov 2022 Volume 10 Number 11 p1009-1098, e94-e106 https://www.thelancet.com/journals/lanres/issue/current Editorial

#### Withdrawal of COVID funding compounds health inequalities

The Lancet Respiratory Medicine

#### **Articles**

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

Robert H Shaw, et al. and the Com-COV Study Group Open Access

#### **Maternal and Child Health Journal**

Volume 26, issue 10, October 2022 <a href="https://link.springer.com/journal/10995/volumes-and-issues/26-10">https://link.springer.com/journal/10995/volumes-and-issues/26-10</a> [Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 42 Issue 8, November 2022

# http://mdm.sagepub.com/content/current

Research article

First published 20 August, 2022 pp. 1078-1086

**COVID-19 and Politically Motivated Reasoning** 

Allegra Maguire, et al.

# **The Milbank Quarterly**

A Multidisciplinary Journal of Population Health and Health Policy Volume 100, Issue 3 Pages: 617-961 September 2022 <a href="https://onlinelibrary.wiley.com/toc/14680009/current">https://onlinelibrary.wiley.com/toc/14680009/current</a> [Reviewed earlier]

#### **Nature**

Volume 611 Issue 7935, 10 November 2022

https://www.nature.com/nature/volumes/611/issues/7935

World View 08 Nov 2022

# **How scientists can inform policy decisions**

You might know what policymakers should know. That doesn't mean you know how to help them to use that information.

**Dewey Murdick** 

# **Nature Biotechnology**

Volume 40 Issue 11, November 2022

https://www.nature.com/nbt/volumes/40/issues/11

*News* 08 Nov 2022

# For hemophilia and thalassemia, a new era of 'one-and-done' gene therapies has arrived

Industry celebrates two newly approved genetic medicines, but patients with these blood disorders may face a long wait, and many will never access them because of their high cost.

Cormac Sheridan

Review Article 03 Nov 2022

# Unlocking the promise of mRNA therapeutics

mRNA therapeutics face more challenges than mRNA vaccines, but solutions are on the horizon. Eduarde Rohner, Ran Yang, Kenneth R. Chien Abstract

The extraordinary success of mRNA vaccines against coronavirus disease 2019 (COVID-19) has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical trials of mRNA therapeutics include studies of paracrine vascular endothelial growth factor (VEGF) mRNA for heart failure and of CRISPR—Cas9 mRNA for a congenital liver-specific storage disease. However, a series of challenges remains to be addressed before mRNA can be established as a general therapeutic modality with broad relevance to both rare and common diseases. An array of new technologies is being developed to surmount these challenges, including approaches to optimize mRNA cargos, lipid carriers with inherent tissue tropism and in vivo percutaneous delivery systems. The judicious integration of these advances may unlock the promise of biologically targeted mRNA therapeutics, beyond vaccines and other immunostimulatory agents, for the treatment of diverse clinical indications.

#### **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed12 Nov 2022) [No new digest content identified]

#### **Nature Genetics**

Volume 54 Issue 11, November 2022 https://www.nature.com/ng/volumes/54/issues/11 Articles

# <u>Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in</u> rheumatoid arthritis

Multi-ancestry genome-wide association analyses identify 124 risk loci for rheumatoid arthritis, of which 34 are novel. A polygenic risk score based on multi-ancestry data showed comparable performance between populations of European and East Asian ancestries. Kazuyoshi Ishiqaki, Saori Sakaue, Soumya Raychaudhuri

**Abstract** 

Rheumatoid arthritis (RA) is a highly heritable complex disease with unknown etiology. Multi-ancestry genetic research of RA promises to improve power to detect genetic signals, fine-mapping resolution and performances of polygenic risk scores (PRS). Here, we present a large-scale genome-wide association study (GWAS) of RA, which includes 276,020 samples from five ancestral groups. We conducted a multi-ancestry meta-analysis and identified 124 loci ( $P < 5 \times 10-8$ ), of which 34 are novel. Candidate genes at the novel loci suggest essential roles of the immune system (for example, TNIP2 and TNFRSF11A) and joint tissues (for example, WISP1) in RA etiology. Multi-ancestry fine-mapping identified putatively causal variants with biological insights (for example, LEF1). Moreover, PRS based on multi-ancestry GWAS outperformed PRS based on single-ancestry GWAS and had comparable performance between populations of European and East Asian ancestries. Our study provides several insights into the etiology of RA and improves the genetic predictability of RA.

#### **Nature Human Behaviour**

Volume 6 Issue 10, October 2022 <a href="https://www.nature.com/nathumbehav/volumes/6/issues/10">https://www.nature.com/nathumbehav/volumes/6/issues/10</a> [Reviewed earlier]

#### **Nature Medicine**

Volume 28 Issue 10, October 2022 <a href="https://www.nature.com/nm/volumes/28/issues/10">https://www.nature.com/nm/volumes/28/issues/10</a> [Reviewed earlier]

# **Nature Reviews Drug Discovery**

Volume 21 Issue 11, November 2022 <a href="https://www.nature.com/nrd/volumes/21/issues/11">https://www.nature.com/nrd/volumes/21/issues/11</a> [New issue; No digest content identified]

#### **Nature Reviews Genetics**

Volume 23 Issue 11, November 2022

https://www.nature.com/nrg/volumes/23/issues/11

Review Article 17 May 2022

### Opportunities and challenges for the use of common controls in sequencing studies

Publicly available sequencing data can be used as external common controls for rare variant analyses but cautious sample ascertainment and processing is needed to avoid bias and confounding. The authors review opportunities and challenges for the robust use of common controls in genetic studies, including study design, infrastructure and quality control considerations.

Genevieve L. Wojcik, Jessica Murphy, Audrey E. Hendricks

# **Nature Reviews Immunology**

Volume 22 Issue 11, November 2022

https://www.nature.com/nri/volumes/22/issues/11

[New issue; No digest content identified]

# **New England Journal of Medicine**

November 10, 2022 Vol. 387 No. 19

https://www.nejm.org/toc/nejm/medical-journal

**Perspective** 

<u>Circulating Poliovirus in New York — New Instance of an Old Problem</u>

M.A. Pallansch

<u>Long-Acting Injectable Antiretrovirals in Incarcerated Populations — Challenges and Opportunities</u>

M.J. Akiyama, A.C. Spaulding, and A.E. Nijhawan

Original Articles

<u>Protection against Omicron from Vaccination and Previous Infection in a Prison System</u>
E.T. Chin and Others

Review Article

### **Monkeypox**

A. Gessain, E. Nakoune, and Y. Yazdanpanah

#### njp Vaccines

https://www.nature.com/npjvaccines/

[Accessed 12 Nov 2022] Article Open Access

Published: 12 November 2022

A potent, broadly protective vaccine against SARS-CoV-2 variants of concern

Ziyan Wang

#### **Pediatrics**

Volume 150, Issue 4 October 2022 <a href="https://publications.aap.org/pediatrics/issue/150/4">https://publications.aap.org/pediatrics/issue/150/4</a> [Reviewed earlier]

#### **PharmacoEconomics**

Volume 40, issue 11, November 2022 <a href="https://link.springer.com/journal/40273/volumes-and-issues/40-11">https://link.springer.com/journal/40273/volumes-and-issues/40-11</a> [New issue; No digest content identified]

# **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 12 Nov 2022) [No new digest content identified]

#### **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 12 Nov 2022) [No new digest content identified]

#### **PLoS Medicine**

http://www.plosmedicine.org/ (Accessed 12 Nov 2022) Perspective

**Infection, immunity, and surveillance of COVID-19** 

Amitabh Bipin Suthar, Christopher Dye Perspective | published 10 Nov 2022 PLOS Medicine https://doi.org/10.1371/journal.pmed.1004132

# <u>Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany</u>

Martin Roessler, Falko Tesch, Manuel Batram, Josephine Jacob, Friedrich Loser, Oliver Weidinger, Danny Wende, Annika Vivirito, Nicole Toepfner, Franz Ehm, Martin Seifert, Oliver Nagel, Christina König, Roland Jucknewitz, Jakob Peter Armann, Reinhard Berner, Marina Treskova-Schwarzbach, Dagmar Hertle, Stefan Scholz, Stefan Stern, Pedro Ballesteros, Stefan Baßler, Barbara Bertele, Uwe Repschläger, Nico Richter, Cordula Riederer, Franziska Sobik, Anja Schramm, Claudia Schulte, Lothar Wieler, Jochen Walker, Christa Scheidt-Nave, Jochen Schmitt

Research Article | published 10 Nov 2022 PLOS Medicine

https://doi.org/10.1371/journal.pmed.1004122

Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland—A multicentre cohort study

Baharak Babouee Flury, Sabine Güsewell, Thomas Egger, Onicio Leal, Angela Brucher, Eva Lemmenmeier, Dorette Meier Kleeb, J. Carsten Möller, Philip Rieder, Markus Rütti, Hans-Ruedi Schmid, Reto Stocker, Danielle Vuichard-Gysin, Benedikt Wiggli, Ulrike Besold, Allison McGeer, Lorenz Risch, Andrée Friedl, Matthias Schlegel, Stefan P. Kuster, Christian R. Kahlert, Philipp Kohler, on behalf of the SURPRISE Study Group

Research Article | published 07 Nov 2022 PLOS Medicine

https://doi.org/10.1371/journal.pmed.1004125

# **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/

[No new digest content identified]

#### **PLoS One**

http://www.plosone.org/

[Accessed 12 Nov 2022]

# <u>Vulnerability in maternal, new-born, and child health in low- and middle-income countries:</u> Findings from a scoping review

Olusesan Ayodeji Makinde, Olalekan A. Uthman, Ifeanyi C. Mgbachi, Nchelem Kokomma Ichegbo, Fatima Abdulaziz Sule, Emmanuel O. Olamijuwon, Babasola O. Okusanya

Research Article | published 11 Nov 2022 PLOS ONE

https://doi.org/10.1371/journal.pone.0276747

# <u>Application of machine learning for multi-community COVID-19 outbreak predictions with</u> wastewater surveillance

Yuehan Ai, Fan He, Emma Lancaster, Jiyoung Lee Research Article | published 10 Nov 2022 PLOS ONE

https://doi.org/10.1371/journal.pone.0277154

# <u>Vaccines and more: The response of Dark Web marketplaces to the ongoing COVID-19 pandemic</u>

Alberto Bracci, Matthieu Nadini, Maxwell Aliapoulios, Damon McCoy, Ian Gray, Alexander Teytelboym, Angela Gallo, Andrea Baronchelli

Research Article | published 10 Nov 2022 PLOS ONE

https://doi.org/10.1371/journal.pone.0275288

#### **PLoS Pathogens**

http://journals.plos.org/plospathogens/

[Accessed 12 Nov 2022]

[No new digest content identified]

#### PNAS - Proceedings of the National Academy of Sciences of the United States

November 8, 2022 vol. 119 no. 45

https://www.pnas.org/toc/pnas/119/45

Brief Report November 2, 2022

Generation of genome-edited chicken and duck lines by adenovirus-mediated in vivo genome editing

Conventional avian genome editing is mediated by isolation, culture, and genome editing of primordial germ cells (PGCs); screening and propagating the genome-edited PGCs; and transplantation of the PGCs into recipient embryos. The PGC-mediated procedures, ...

Joonbum Lee, Dong-Hwan Kim, [...] Kichoon Lee

# **Prehospital & Disaster Medicine**

Volume 37 - Issue 5 - October 2022 <a href="https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue">https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</a> [Reviewed earlier]

#### **Preventive Medicine**

Volume 163 October 2022 <a href="https://www.sciencedirect.com/journal/preventive-medicine/vol/163/suppl/C">https://www.sciencedirect.com/journal/preventive-medicine/vol/163/suppl/C</a> [Reviewed earlier]

# **Proceedings of the Royal Society B**

09 November 2022 Volume 289 Issue 1986 <a href="https://royalsocietypublishing.org/toc/rspb/current">https://royalsocietypublishing.org/toc/rspb/current</a> [New issue; No digest content identified]

#### **Public Health**

Volume 212 Pages 1-110 (November 2022) https://www.sciencedirect.com/journal/public-health/vol/212/suppl/C Review article Full text access

<u>COVID-19 vaccine acceptance and hesitancy among patients with cancer: a systematic review and meta-analysis</u>

K.I.P. Prabani, I. Weerasekara, H.D.W.T. Damayanthi Pages 66-75

Review article Full text access

Factors influencing international collaboration on the prevention of COVID-19

M. Hameed, M. Najafi, S. Cheeti, A. Sheokand, ... S. Desai Pages 95-101

#### **Public Health Ethics**

Volume 15, Issue 1, April 2022 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

# **Public Health Reports**

Volume 137 Issue 5, September/October 2022 <a href="https://journals.sagepub.com/toc/phrg/137/5">https://journals.sagepub.com/toc/phrg/137/5</a>

#### [Reviewed earlier]

#### **Qualitative Health Research**

Volume 32 Issue 13, November 2022

https://journals.sagepub.com/toc/ghra/current

Research article First published 30 September, 2022pp. 1993–2005

Reflection of Types of Prosocial Behavior During COVID-19 in Collectivistic Asian Countries—India and Indonesia

Shanu Shukla, Sushanta Kumar Mishra, Rahmi Dian Agustino *Abstract* 

COVID-19 is an infectious disease that has widened the gap between victims and non-victims in society. Understanding how individuals support and assist COVID-19 sufferers in a pandemic crisis is critical. Thus, this study aims to qualitatively evaluate the prosocial intention and types of prosocial behavior toward COVID-19 victims by low socioeconomic individuals from India and Indonesia's collectivistic societies. We conducted semi-structured and in-depth interviews during the lockdown from March to May 2020, via phone and in-person, using a purposive selection of respondents (total n = 50). The data were analyzed using the qualitative synthesis method. Five themes were discovered: 1) too scared to help, 2) love to help but scared: moral dilemma, 3) informing authority who knows how to handle, 4) caring, sharing, and supporting, but with a distance, and 5) helping at one's personal health risk. This study highlights that prosocial intentions range from minor acts of kindness to self-harm and out-of-bounds acts of kindness for COVID-19 victims.

#### **Research Ethics**

Volume 18 Issue 4, October 2022 <a href="http://journals.sagepub.com/toc/reab/current">http://journals.sagepub.com/toc/reab/current</a> [Reviewed earlier]

#### **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 12 Nov 2022] [No new digest content identified]

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en

Selected Articles

8 Nov 2022

<u>Suitability of two WHO research and development initiatives for COVID-19 to promote</u>
<u>equitable innovation: the Access to COVID-19 Tools Accelerator and COVID-19 Technology</u>
<u>Access Pool</u>

Original research | English |

8 Nov 2022

# Reporting on antibiotic use patterns using the WHO Access, Watch, Reserve classification in the Caribbean

Original research | English |

8 Nov 2022

The Every Woman Every Child initiative: supporting countries in Latin America and the Caribbean to reduce social inequalities in health

Special report | Spanish |

# **Risk Analysis**

Volume 42, Issue 9 Pages: 1893-2124 September 2022 <a href="https://onlinelibrary.wiley.com/toc/15396924/current">https://onlinelibrary.wiley.com/toc/15396924/current</a>

Special Series: Systemic Risks

[Reviewed earlier]

# **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56

[Accessed 12 Nov 2022]

Original Research

<u>Public Risk Perception Attribution Model and Governance Path in COVID-19: A Perspective Based on Risk Information</u>

Wang J, Guo C, Lin T

Risk Management and Healthcare Policy 2022, 15:2097-2113

Published Date: 8 November 2022

### **Science**

Volume 378| Issue 6620| 11 Nov 2022 https://www.science.org/toc/science/current [New issue; No digest content identified]

# **Science and Engineering Ethics**

Volume 28, issue 5, October 2022 <a href="https://link.springer.com/journal/11948/volumes-and-issues/28-5">https://link.springer.com/journal/11948/volumes-and-issues/28-5</a> [Reviewed earlier]

#### **Science Translational Medicine**

Volume 14| Issue 670| 9 Nov 2022 https://www.science.org/toc/stm/current Viewpoints

### What's next for cancer vaccines

BY Juraj Adamik, Lisa H. Butterfield 09 Nov 2022

Cancer vaccination can promote antitumor immunity in patients, and optimization of components and new combinations are needed for clinical efficacy.

#### Reviews

# In vivo gene immunotherapy for cancer

BY David Mai, Carl H. June, Neil C. Sheppard 09 Nov 2022

Emerging technologies are enabling the delivery and modulation of genes in immune cells or tumor cells in vivo to drive antitumor immunity.

#### **Social Science & Medicine**

Volume 313 November 2022

https://www.sciencedirect.com/journal/social-science-and-medicine/vol/313/suppl/C

Regular articles

Research article Abstract only

<u>Lived experience with sickle cell disease: Predictors of altruistic participation in clinical</u> research

Marilyn S. Baffoe-Bonnie

Article 115353

Research article Open access

"We need to protect each other": COVID-19 vaccination intentions and concerns among Racialized minority and Indigenous Peoples in Canada

Terra Manca, Robin M. Humble, Laura Aylsworth, Eunah Cha, ... Shannon E. MacDonald Article 115400

#### **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 12 Nov 2022] [No new digest content identified]

#### **Theoretical Medicine and Bioethics**

Volume 43, issue 2-3, June 2022 <a href="https://link.springer.com/journal/1117/volumes-and-issues/43-2">https://link.springer.com/journal/1117/volumes-and-issues/43-2</a> [Reviewed earlier]

#### **Travel Medicine and Infectious Diseases**

Volume 50 November-December 2022

https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/50/suppl/C *Editorial Full text access* 

FIFA World Cup 2022 in Qatar: Mitigating the risk of imported infections amid the COVID-19 pandemic, monkeypox outbreak and other emerging diseases

Ranjit Sah, Najim Z. Alshahrani, Pooja Shah, Aroop Mohanty, ... Alfonso J. Rodriguez-Morales Article 102450

Review article Full text access

A review on insights and lessons from COVID-19 to the prevent of monkeypox pandemic

Sara Hemati, Marzieh Farhadkhani, Samira Sanami, Fazel Mohammadi-Moghadam Article 102441

Research article Full text access

<u>Prevalence and factors associated with not receiving the booster dose of the COVID-19 vaccine in adults in Latin America and the Caribbean</u>

Diego Urrunaga-Pastor, Daniel Fernandez-Guzman, Brenda Caira-Chuquineyra, Percy Herrera-Añazco, ... Guido Bendezu-Quispe

Article 102409

### **Tropical Medicine & International Health**

Volume 27, Issue 10 Pages: i-iv, 841-940 October 2022 <a href="https://onlinelibrary.wiley.com/toc/13653156/current">https://onlinelibrary.wiley.com/toc/13653156/current</a> [Reviewed earlier]

#### **Vaccine**

Volume 40, Issue 45 Pages 6445-6566 (26 October 2022) https://www.sciencedirect.com/journal/vaccine/vol/40/issue/45 Research article Open access

Misinformation about vaccine safety and uptake of COVID-19 vaccines among adults and 5-11-year-olds in the United States

Daniel Romer, Kenneth M. Winneg, Patrick E. Jamieson, Colleen Brensinger, Kathleen H. Jamieson Pages 6463-6470

Research article Full text access

<u>Parental health beliefs, intention, and strategies about covid-19 vaccine for their children:</u>
A cross-sectional analysis from five Arab countries in the Middle East

Ali Haider Mohammed, Bassam Abdul Rasool Hassan, Abdulrasool M. Wayyes, Ansam Qassim Gadhban, ... Fares Mohammed Saeed Muthanna

Pages 6549-6557

Research article Abstract only

<u>Development of a road map to scale up the uptake and utilization of influenza vaccine in 22 countries of Eastern Mediterranean Region</u>

Abrar Ahmad Chughtai, Shaza Mohammed, Lubna Al Ariqi, Margaret McCarron, ... Wasiq Khan Pages 6558-6565

#### **Value in Health**

December 2022 Volume 25 Issue 12 p1925-2080 <a href="https://www.valueinhealthjournal.com/current">https://www.valueinhealthjournal.com/current</a> [New issue; No digest content identified]

# :::::::

### Contents [click to move among sections]

- :: Coronavirus [COVID-19] WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

:::::::

# **Pre-Print Servers**

### **Gates Open Research**

https://gatesopenresearch.org/browse/articles Selected Research No new digest content identified.

#### medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Filter: All articles]
Selected Research

# Health, socioeconomic and genetic predictors of COVID-19 vaccination uptake: a nationwide machine-learning study

Tuomo Hartonen, Bradley Jermy, Hanna Sonajalg, Pekka Vartiainen, Kristi Krebs, Andrius Vabalas, FinnGen, Estonian Biobank research team, Tuija Leino, Hanna Nohynek, Jonas Sivela, Reedik Magi, Mark J Daly, Hanna M Ollila, Lili Milani, Markus Perola, Samuli Ripatti, Andrea Ganna medRxiv 2022.11.11.22282213; doi: https://doi.org/10.1101/2022.11.11.22282213

# <u>Disability and Post-traumatic Stress Symptoms in the Ukrainian General Population During</u> the 2022 Russian Invasion

Tarandeep S Kang, Robin Goodwin, Yaira Hamama-Raz, Elazar Leshem, Menachem Ben-Ezra medRxiv 2022.11.07.22282027; doi: https://doi.org/10.1101/2022.11.07.22282027

#### **Genomic Characterization of Dengue Virus Outbreak in 2022 from Pakistan**

Massab Umair, Zaira Rehman, Syed Adnan Haider, Qasim Ali, Zunera Jamal, Muhammad Ammar, Rabia Hakim, Shaheen Bibi, Rida Sagheer, Muhammad Salman, Aamer Ikram medRxiv 2022.11.07.22281924; doi: https://doi.org/10.1101/2022.11.07.22281924

#### Prioritizing interventions for cholera control in Kenya, 2015-2020

Waqo Boru, Shaoming Xiao, Patrick Amoth, David Kareko, Daniel Langat, Ian Were, Mohammad Ali, David A. Sack, Elizabeth C. Lee, Amanda K. Debes medRxiv 2022.11.07.22281877; doi: https://doi.org/10.1101/2022.11.07.22281877

### **Evaluating the use of dose-sparing vaccination strategies for Monkeypox**

Dobromir Dimitrov, Blythe Adamson, Laura Matrajt

medRxiv 2022.11.04.22281966; doi: https://doi.org/10.1101/2022.11.04.22281966

# A comprehensive knowledgebase of known and predicted human genetic variants associated with COVID-19 susceptibility and severity

Meltem Ece Kars, David Stein, Çiğdem Sevim Bayrak, Peter D Stenson, David N Cooper, Yuval Itan medRxiv 2022.11.03.22281867; doi: https://doi.org/10.1101/2022.11.03.22281867

### Systematic review of the prevalence of Long Covid

Mirembe Woodrow, Charles Carey, Nida Ziauddeen, Rebecca Thomas, Athena Akrami, Vittoria Lutje, Darren C Greenwood, Nisreen A Alwan

medRxiv 2022.11.06.22281979; doi: https://doi.org/10.1101/2022.11.06.22281979

# Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older

Hui-Lee Wong, Ellen Tworkoski, Cindy Ke Zhou, Mao Hu, Deborah Thompson, Bradley Lufkin, Rose Do, Laurie Feinberg, Yoganand Chillarige, Rositsa Dimova, Patricia Lloyd, Thomas MaCurdy, Richard A. Forshee, Jeffrey Kelman, Azadeh Shoaibi, Steven A. Anderson

medRxiv 2022.11.04.22281910; doi: https://doi.org/10.1101/2022.11.04.22281910

# <u>Understanding Knowledge, Attitudes and Practices on Ebola Virus Disease: A Multi-Site Mixed Methods Survey on Preparedness in Rwanda</u>

Janvier Karuhije, Menelas Nkeshimana, Fathiah Zakham, Benjamin Hewins, Justin Rutayisire, Gustavo S. Martinez, David Kelvin, Pacifique Ndishimye

medRxiv 2022.11.03.22281885; doi: https://doi.org/10.1101/2022.11.03.22281885

# <u>Citizen involvement in research on technological innovations for health, care or well-being:</u> <u>a scoping review</u>

Catharina M. van Leersum, Christina Jaschinski, Marloes Bults, Johan van der Zwart medRxiv 2022.11.03.22281892; doi: https://doi.org/10.1101/2022.11.03.22281892

# Real-time forecasting the trajectory of monkeypox outbreaks at the national and global levels, July — October 2022

Amanda Bleichrodt, Sushma Dahal, Kevin Maloney, Lisa Casanova, Ruiyan Luo, Gerardo Chowell medRxiv 2022.11.02.22281844; doi: https://doi.org/10.1101/2022.11.02.22281844

### **OSF Pre-prints**

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences [Accessed 12 Nov 2022]

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

# World Health Organization Is Losing Public Credibility Towards Health-Sensitive Topics: Infodemiological Analysis of Facebook Users' Reactions

Alessandro Rovetta

Last edited: Nov 10, 2022 UTC

Social and Behavioral Sciences Communication Health Communication

Background The scientific infodemic constitutes one of the greatest threats to public health and safety today. The credibility of the main dissemination agencies is an essential tool for adhering to measures to preserve public health.

**OSF Preprints** 

# **Wellcome Open Research** [to 12 Nov 2022]

https://wellcomeopenresearch.org/browse/articles

[Accessed 12 Nov 2022]

Selected Research

Research Article metrics AWAITING PEER REVIEW

# <u>Issue-networks as omitted publics in the construction of #rarediseaseday discourse</u>

[version 1; peer review: awaiting peer review]

Matthew Hanchard Peer Reviewers Invited Funder Wellcome Trust PUBLISHED 09 Nov 2022

\* \* \* \*

# **Think Tanks**

**Brookings** [to12 Nov 2022] http://www.brookings.edu/ Latest Research [Selected] No new digest content identified

### **Center for Global Development** [to 12 Nov 2022]

https://www.cgdev.org/ All Research [Selected] POLICY PAPERS

# <u>Understanding the Costs and Benefits of Investing in Laboratory Systems in African Countries</u>

Clementine Fu et al.

November 10, 2022

Laboratories are fundamental components of health systems, but investments in strengthening laboratory systems are often inconsistent and inadequate in African countries. This paper qualitatively establishes the complex costs and benefits of strengthening laboratory capacity and systems within and a...

#### CASE STUDIES

# CGD Contributions to Enhancing the "Value for Money" of HIV/AIDS Financing

Cordelia Kenney

November 10, 2022

This case study examines the extent to which CGD's work may have impacted the adoption of a VfM agenda at HIV donor agencies and analyzes the evidentiary basis for claims regarding the specific mechanisms by which it did so.

POLICY PAPERS

# A Global Development Paradigm for a World in Crisis

Rachael Calleja et al. November 08, 2022

This paper explores how and whether responses to COVID-19, particularly from non-DAC actors, have deepened the transition from an "international" to a "global" development paradigm, and it considers implications for the future of development cooperation.

# **Chatham House** [to 12 Nov 2022]

https://www.chathamhouse.org/ Selected Analysis, Comment No new digest content identified

CSIS [to12 Nov 2022] https://www.csis.org/ Selected Reports Report Report

### **Transforming Health Crises with Pandemic Therapies**

November 9, 2022 | <u>Katherine E. Bliss</u>, <u>J. Stephen Morrison</u> A final report from the CSIS Commission on Strengthening America's Health Security's working group on Covid-19 therapies discusses how to strengthen U.S. leadership and global action to ensure development of, access to, and uptake of Covid-19 therapies worldwide.

### **Kaiser Family Foundation** [to12 Nov 2022]

https://www.kff.org/search/?post\_type=press-release Press Releases No new digest content identified.

# **ODI [Overseas Development Institute]** [to12 Nov 2022]

https://odi.org/en/publications/ Publications No new digest content identified.

#### **Pew Research Center** [to 12 Nov 2022]

https://www.pewresearch.org/ Latest Publications short read | Nov 10, 2022

### Americans report more engagement with science news than in 2017

More than half of U.S. adults (56%) say they talk about science news with others at least a few times a month.

**Rand** [to 12 Nov 2022]

https://www.rand.org/pubs.html

Reports, Selected Journal Articles

Journal Article

# <u>Paying for PrEP: A Qualitative Study of Cost Factors That Impact Pre-Exposure Prophylaxis Uptake in the US</u>

We conducted semi-structured interviews with 25 men who have sex with men who presented for routine health care at a STD clinic about their experiences with accessing and paying for PrEP. Nov 11, 2022

Zachary Predmore, Megan Hoopes, Philip A. Chan

Dissertation

### **Comics as Policy Communication: An Exploratory Analysis**

Conducts an exploratory analysis of ways policy communication can be improved using policy comics. Nov 9, 2022

Karen Lee

Research Brief

# <u>Infection Control in Long-Term Care: Decisionmaking Lessons from the COVID-19</u> Pandemic

The COVID-19 pandemic highlighted a need to transform the decisionmaking culture in long-term care to make it more inclusive of residents, staff, and others who are affected by infection-control policies in these facilities.

Nov 9, 2022

Lori Frank, Thomas W. Concannon, Jordan M. Harrison, Sarah Zelazny

**Urban Institute** [to 12 Nov 2022]

https://www.urban.org/publications

**New Research Publications** 

Brief

**Immigrant Families Faced Multiple Barriers to Safety Net Programs in 2021** 

November 10, 2022

**World Economic Forum** [to 12 Nov 2022]

https://agenda.weforum.org/news/

Media

<u>World Economic Forum Alliance Adopts Newly Released Guide to Strengthen Private Sector</u>
Action on Air Pollution

News 10 Nov 2022

<u>World Economic Forum and Partners Launch Guide for Sustainable Ocean-based Carbon</u>

Markets at COP27

News 09 Nov 2022

World's Leading Agri-Commodity Companies Deliver Roadmap to Reduce Emissions from Land Use Change

News 07 Nov 2022

# <u>First Movers Coalition Commits \$12 billion to Commercialize Zero-Carbon Tech, Cut</u> Emissions

News 07 Nov 2022

# **Selected Media**

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, <u>PATH</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.